

Date Submitted: 2025-01-08 11:43:37

Confirmation Number: 1893433

Template: CIHR Biosketch

Dr. Moishe Liberman

Correspondence language: English

Sex: Male

Date of Birth: 10/16

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

CHUM - Centre de Recherche

Room: R04.402-1

900 Rue Saint-Denis

Montreal Quebec H2X 0A9

Canada

Telephone

Fax 514-4127855

Laboratory (*) 514-890-8000 extension: 26832

Email

Work (*) moishe.liberman@umontreal.ca

Website

Corporate www.cetoc.ca



Protected when completed

Dr. Moishe Liberman

Degrees

2004/9 - 2008/4	Doctorate, Doctorate of Philosophy, McGill University Degree Status: Completed
1996/9 - 2000/6	Doctorate, MDCM - Doctor of Medicine and Surgery - M.D., McGill University Degree Status: Completed

Credentials

2016/5	American Association of Thoracic Surgeons - Member, American Association of Thoracic Surgeons (AATS)
2011/8	Fellow of the American College of Surgeons, American College of Surgeons
2011/1	Specialist Certificate - Thoracic Surgery, College des Médecins du Québec
2001/1	Licentiate of the Medical Council of Canada (LMCC), Medical Council of Canada

Recognitions

2024/1	Prix d'excellence 2023 du CRCHUM: Prix Carrière CRCHUM
2020/6	Full Professor (PTG), University of Montreal Université de Montréal
2016/5	Active Member American Association for Thoracic Surgery (AATS). First Application American Association for Thoracic Surgery
2009/3	Chaire Marcel et Rolande Gosselin Université de Montréal
1996/9	Dean's Honor Roll McGill University - Faculty of Arts and Science

Employment

2022/1	Chief Medical Officer Ditch Labs
2021/10	Chief Medical Officer AssistIQ
2021/1	Director - TID Lab CRCHUM

2020/12	Chief Medical Officer Endocision
2020/3	Committee Member - Comité de surveillance - Endoscopie CHUM - COVID-19 CHUM
2020/3	Regular Member - FRQS-RRCancer Research Committee FRQS-RRCancer Research Committee
2019/1	Dépistage cancer poumon : groupe de travail pour projet de démonstration. Gouvernement du Québec. Gouvernement du Québec.
2019/1	Unite d'Innovations Therapeutiques (UIT) - Comité Aviseur. CRCHUM CRCHUM
2018/1	American College of Chest Physicians Guidelines Committee for the Management of Central Airway Obstruction American College of Chest Physicians
2018/1	American Thoracic Society / American Association for Bronchology and Interventional Pulmonology Guideline Committee Working Group Executive Committee for the Management of Indwelling/Tunneled Pleural Catheter Infections American Thoracic Society / American Association for Bronchology and Interventional Pulmonology
2018/1	Abstract Selection Committee – International Association for the Study of Lung Cancer Annual Meeting 2018 International Association for the Study of Lung Cancer (IASLC)
2017/1	Committee de Recherche Clinique – CHUM / CR-CHUM CR-cHUM
2017/1	American College of Chest Physicians (ACCP) Guideline Committee on Cryobiopsy in Interstitial Lung Disease American College of Chest Physicians (ACCP)
2017/1	ALLIANCE NCI Trials Working Group National Cancer Institute
2017/1	Committee d'Éndoscopie –Nouveau CHUM CHUM
2016/6	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2016 NA, NA, International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2016/6	Postgraduate Course Director. American Association of Thoracic Surgery (AATS) Meeting. Boston, MA; 2017 NA, NA, American Association of Thoracic Surgery (AATS)
2016/1	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2016 NA, NA, Society of Thoracic Surgeons
2016/1	Royal College of Physicians and Surgeons Region 4 Representative. Thoracic Surgery Committee. NA, NA, Royal College of Physicians and Surgeons of Canada
2016/1	Editorial Board - Journal of Thoracic Disease NA, NA, Journal of Thoracic Disease
2016/1	American Thoracic Society (ATS) – Education Committee Member NA, NA, American Thoracic Society

2016/1	Journal Reviewer - Journal of Heart and Lung Transplantation NA, NA, Journal of Heart and Lung Transplantation
2016/1	International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Annual Meeting Program Committee Member NA, NA, International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2016/1	American Thoracic Society – Core Curriculum Committee Member – Lung Cancer Staging American Thoracic Society
2016/1	International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Annual Meeting Program Committee Member International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2016/1	Président, Comité Réseau pour la Cancérologie Oesophagienne, Gouvernement du Québec. Gouvernement du Québec
2016/1	American Thoracic Society – Education Committee Member American Thoracic Society
2016/1	Royal College of Physicians and Surgeons Region 4 Representative. Thoracic Surgery Committee. Royal College of Physicians and Surgeons
2015/1	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2015 NA, NA, Society of Thoracic Surgeons
2015/1	Committee de Pilotage, Recherche Clinique – CRCHUM NA, NA, Centre de Recherche du CHUM
2015/1	Journal Reviewer - Respiration NA, NA, Respiration
2015/1	Committee de Transition Endoscopie –CHUM NA, NA, Centre hospitalier de l'Université de Montréal
2015/1	Exam Question Writing Committee – Interventional Pulmonology Board Exams. AAIPPD. NA, NA, American Association of Interventional Pulmonology Program Directors
2015/1	Journal Reviewer - Chest NA, NA, American College of Chest Physicians (ACCP)
2015/1	Lung cancer Screening Committee – Province of Quebec, Canada NA, NA, Province of Quebec
2015/1	Committee de Transition Endoscopie – CHUM CHUM
2015/1	Quebec Lung Cancer Screening Committee – Province of Quebec, Canada Government of the Province of Quebec, Canada
2015/1	Exam Question Writing Committee – Interventional Pulmonology Board Exams. AAIPPD. American Association of Interventional Pulmonology Program Directors
2015/1	Committee de Pilotage, Recherche Clinique – CRCHUM CR-CHUM
2014/1	Journal Reviewer - Annals of Palliative Medicine NA, NA, Annals of Palliative Medicine
2014/1	Journal Reviewer - Surgical Endoscopy NA, NA, Surgical Endoscopy

2014/1	Journal Reviewer - Clinical Respiratory Journal NA, NA, Clinical Respiratory Journal
2014/1	MSSS Lung Cancer Regionalization Committee NA, NA, Province of Quebec - Ministere de Cancer
2014/1	Association des Chirugiens Thoracique du Quebec (ACTQ) – Vice President NA, NA, Association des Chirugiens Thoracique du Quebec (ACTQ)
2014/1	National Cancer Institute (NCI) – Lung Cancer Subgroup Committee Member NA, NA, National Cancer Institute
2014/1	MSSS Lung Cancer Regionalization Committee Gouvernement du Quebec
2014/1	NCIC CTG Disease Site Committee Centre Representative - Lung Cancer National Cancer Institute of Canada (NCIC)
2014/1	Association des Chirugiens Thoracique du Quebec (ACTQ) – Vice President Association des Chirugiens Thoracique du Quebec (ACTQ)
2013/8	Associate Professor Surgery, MEDICINE, Université de Montréal
2013/6	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2014 Society of Thoracic Surgeons
2013/5	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2014 NA, NA, Society of Thoracic Surgeons
2013/1	Association of Interventional Pulmonology Program Directors (AIPPD) – Committee Member NA, NA, Association of Interventional Pulmonology Program Directors
2013/1	American College of Surgeons / Alliance Thoracic Surgery Standards Group NA, NA, American College of Surgeons
2013/1	Society of Thoracic Surgeons. Course Director – Advanced Endoscopy for Thoracic Surgeons NA, NA, Society of Thoracic Surgeons
2013/1	Comité de travail sur la trajectoire du cancer du poumon – Agence de la Santé et des Services Sociaux de Montréal. NA, NA, Agence de la Santé et des Services Sociaux de Montréal
2013/1	American College of Chest Physicians (ACCP) Interventional Pulmonology Royal Commission Working Group NA, NA, American College of Chest Physicians (ACCP)
2013/1	Journal Reviewer NA, NA, OMICS Journal of Radiology
2013/1	Journal Reviewer - European Journal of Cardiothoracic Surgery (EJCTS) NA, NA, EJCTS
2013/1	Comité de travail sur la trajectoire du cancer du poumon – Agence de la Santé et des Services Sociaux de Montréal. Agence de la Santé et des Services Sociaux de Montréal.
2013/1	Association of Interventional Pulmonology Program Directors (AIPPD) – Committee Member Association of Interventional Pulmonology Program Directors (AIPPD)

2013/1 American College of Chest Physicians (ACCP) Interventional Pulmonology Royal Commission Working Group
American College of Chest Physicians (ACCP)

2013/1 American College of Surgeons / Alliance Thoracic Surgery Standards Group
American College of Surgeons

2012/1 Clinical Research Representative - Centre Intégré de Cancérologie
NA, NA, Centre hospitalier de l'Université de Montréal

2012/1 Exam Question Writing Committee
NA, NA, Self Education Self Assessment in Thoracic Surgery (SESATS)

2012/1 Member - The CARE Program provides an opportunity for Canadian specialists to discuss news and information related to lung cancer
NA, NA, The CARE (Community, Academic & Research Education)

2012/1 Clinical Research Representative – Centre Intégré du Cancérologie du CHUM
CR-CHUM

2011/1 Scientific Merit Evaluation Committee Member
Surgery, MEDICINE, Université de Montréal

2011/1 Member, International Thymoma Registry
NA, NA, European Society of Thoracic Surgery (ESTS)

2011/1 Member / Researcher, Montreal Cancer Institute. Montreal, Quebec, Canada.
NA, NA, Montreal Cancer Institute

2011/1 Journal Reviewer
NA, NA, World Journal of Surgical Oncology

2011/1 Preceptor - Groupe d'intérêt en chirurgie de l'Université de Montréal (GICUM)
Undergraduate Education, Medicine, University of Montreal

2011/1 Journal Reviewer
NA, NA, Annals of Surgical Oncology

2011/1 Member, International Thymoma Registry. European Society of Thoracic Surgery (ESTS).
European Society of Thoracic Surgery (ESTS)

2010/6 Event Organizer / Chairman Diagnostic and Therapeutic Thoracic Endoscopy 2010 (June 3rd and 4th)
NA, NA, Division of Thoracic Surgery

2010/1 Journal Reviewer
NA, NA, Canadian Journal of Diabetes

2010/1 Associate Journal Editor
NA, NA, Diseases of the Esophagus

2010/1 Research Committee
NA, NA, Canadian Association of Thoracic Surgeons (CATS)

2010/1 Organizer – General Thoracic Surgery Journal Club, CHUM
SURGERY, MEDICINE, Centre hospitalier de l'Université de Montréal

2010/1 Journal Reviewer
NA, NA, Annals of Thoracic Surgery

2010/1 Director, Advanced Thoracic Interventional Endoscopy Fellowship
Surgery, MEDICINE, Université de Montréal

2010/1 Director, Advanced Thoracic Interventional Endoscopy Fellowship – U Montreal
SURGERY, MEDICINE, Centre Hospitalier de l'Université de Montréal

2010/1	Research Committee Member NA, NA, Canadian Association of Thoracic Surgeons (CATS)
2009/7	Research Committee Member SURGERY, MEDICINE, Université de Montréal
2009/3	Director, CETOC - Centre d'Évaluation Trachéo-Bronchique et Oesophagienne du CHUM SURGERY, MEDICINE, Centre hospitalier de l'Université de Montréal
2009/3	Attending Thoracic Surgeon SURGERY, MEDICINE, Centre hospitalier de l'Université de Montréal
2009/1	Director of Research, Division of Thoracic Surgery Surgery, MEDICINE, Université de Montréal
2009/1	Journal Reviewer NA, NA, Journal of Thoracic and Cardiovascular Surgery (JTCVS)
2009/1	Journal Reviewer NA, NA, Annals of Thoracic Surgery
2009/1	Journal Reviewer NA, NA, Diseases of the Esophagus
2009/1	Journal Reviewer NA, NA, World Journal of Surgical Oncology
2009/1	Journal Reviewer NA, NA, Journal of Thoracic Cancer
2008/4	Researcher SURGERY, MEDICINE, Centre hospitalier de l'Université de Montréal
2008/1	Journal Reviewer NA, NA, Canadian Respiratory Journal
2008/1	Journal Reviewer NA, NA, Journal of Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
2007/6	Journal Reviewer NA, NA, Institute of Health Economics (IHE)
2006/1	Journal Reviewer NA, NA, Canadian Medical Association Journal (CMAJ)
2003/8	Associate Researcher SURGERY, MEDICINE, Hôpital du Sacré-Coeur de Montréal
2003/1	Invited Lecturer - Principles of Surgery (POS) Review Course SURGERY, MEDICINE, McGill University Health Centre
2002/9	Instructor of Surface and Clinical Anatomy Medicine, Faculty of, MEDICINE, McGill University
2001/2	Advanced Trauma Life Support Instructor SURGERY, MEDICINE, Montreal General Hospital
2000/1	Team Member - National Trauma Research Program NA, NA, Programme National de Traumatisme
2020/1 - 2020/12	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2020 International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)

2020/1 - 2020/12	Abstract Selection Committee – Society of Thoracic Surgeons (STS) Annual Meeting 2020 Society of Thoracic Surgeons (STS)
2020/1 - 2020/12	Abstract Selection Committee – American Association for Thoracic Surgery (AATS) Annual Meeting 2020 American Association for Thoracic Surgery (AATS)
2019/1 - 2019/12	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2019 International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2017/1 - 2019/1	INESS. Expert Medicale. Évaluer divers aspects de la chirurgie du cancer de l'oesophage. Institut national d'excellence en santé et en services sociaux, Quebec
2018/1 - 2018/12	Abstract Selection Committee – Society of Thoracic Surgeons (STS) Annual Meeting 2019 Society of Thoracic Surgeons (STS)
2018/1 - 2018/12	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2018 International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2018/1 - 2018/12	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2018 Society of Thoracic Surgeons
2018/1 - 2018/12	Abstract Selection Committee – American Association for Thoracic Surgery (AATS) Annual Meeting 2019 American Association for Thoracic Surgery (AATS)
2013/1 - 2018/1	Society of Thoracic Surgeons – STS University. Course Director – Advanced Endoscopy for Thoracic Surgeons Society of Thoracic Surgeons
2017/1 - 2017/12	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2017 ISMICS
2017/1 - 2017/12	Postgraduate Course Director. American Association of Thoracic Surgery (AATS) Meeting. Boston, MA; April 2017 American Association of Thoracic Surgery (AATS)
2016/1 - 2017/1	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2016 Society of Thoracic Surgeons
2016/1 - 2016/12	Abstract Selection Committee – International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS); 2016 International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)
2012/1 - 2015/12	Comité de Planification Stratégique - Axe Technologies Avancées NA, NA, Centre hospitalier de l'Université de Montréal
2012/1 - 2015/12	Comité de Planification Stratégique - Domaine Imagerie NA, NA, Centre hospitalier de l'Université de Montréal
2012/1 - 2015/12	Comité de Planification Stratégique - Axe Cancérologie NA, NA, Centre hospitalier de l'Université de Montréal
2011/1 - 2015/12	Comité de Planification Stratégique du CHUM 2011-2015 – Axe Cancérologie CHUM
2011/1 - 2015/12	Comité de Planification Stratégique du CHUM 2011-2015 – Axe Technologies Avancées CHUM

2011/1 - 2015/12	Comité de Planification Stratégique du CHUM 2011-2015 – Domaine Imagerie CHUM
2014/1 - 2015/1	Abstract Selection Committee – Society of Thoracic Surgeons Annual Meeting 2015 Society of Thoracic Surgeons
2013/1 - 2015/1	American College of Surgeons / Alliance Thoracic Surgery Standards Group NA, NA, American College of Surgeons
2013/1 - 2014/12	Organizing Committee – Groupe d'Étude en Oncologie du Québec (GEOQ) Équipe de Plans Thérapeutiques Pour les Patients Atteints de Cancer du Poumon Groupe d'Étude en Oncologie du Québec (GEOQ)
2012/1 - 2014/2	Member - The CARE (Community, Academic & Research Education) Program. The focus of the CARE program and working groups is to create educational outputs for Canadian specialists. The CARE program provides an opportunity for Canadian specialists to dis CARE (Community, Academic & Research Education) Program
2013/1 - 2014/1	Organizing Committee – Groupe d'Étude en Oncologie du Québec (GEOQ) Équipe de Plans Thérapeutiques Pour les Patients Atteints de Cancer du Poumon NA, NA, Groupe d'Étude en Oncologie du Québec (GEOQ)
2012/1 - 2013/12	Exam Question Writing Committee – Self-Education Self Assessment in Thoracic Surgery (SESATS) American Board of Cardio-Thoracic Surgery
2009/1 - 2013/8	Assistant Professor Surgery, MEDICINE, Université de Montréal
2009/1 - 2013/7	Workforce on Evidence-Based Surgery Committee Member NA, NA, Society of Thoracic Surgeons
2010/1 - 2012/7	Workforce on Annual Meeting (Surgical Symposia Task Force) NA, NA, Society of Thoracic Surgeons
2000/7 - 2006/6	General Surgery Resident SURGERY, MEDICINE, McGill University Health Centre
2002/9 - 2004/6	Instructor of Human Anatomy Medicine, Faculty of, MEDICINE, McGill University
1997/1 - 2002/7	Research Assistant Surgery, MEDICINE, McGill University
1997/1 - 2002/7	Research Assistant SURGERY, MEDICINE, Montreal General Hospital

Affiliations

The primary affiliation is denoted by (*)

(*) 2009/1 Thoracic Surgeon, Centre hospitalier de l'Université de Montréal

Research Funding History

Awarded [n=13]

2009/3 - 2025/6 Gosselin Chair in Thoracic Surgical Oncology. University of Montreal

Principal Applicant

Funding Sources:

University of Montreal

Research Chairs

Total Funding - 1,000,000

	Funding Competitive?: Yes
2024/12 - 2024/12 Principal Applicant	Biobanque vivante de nouvelle génération afin d'éclairer de nouveaux biomarqueurs et approches thérapeutiques dans le cancer du poumon non à petites cellules Funding Sources: Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM) Biobanque Total Funding - 250,000 Funding Competitive?: Yes
2024/1 - 2024/12 Principal Applicant	Système de localisation de perforation pulmonaire : LungLLS (Leak Localization System) Funding Sources: Axelys Axelys Grant Total Funding - 577,703 Funding Competitive?: Yes
2024/8 - 2024/8 Principal Applicant	Axelys Grant Funding Sources: Axelys INNOVATIONS D'AVENIR Total Funding - 577,703 Funding Competitive?: Yes
2023/1 - 2023/1 Co-applicant	NEEDS Trial - CIHR Funding Sources: Canadian Institutes of Health Research (CIHR) NEEDS Trial Total Funding - 1,800,000 Funding Competitive?: Yes
2020/9 - 2022/9 Principal Investigator	Evidence-Based Technology Assessment and Evaluation of Mediastinal Robotic Surgery at the Centre Hospitalier de l'Université de Montréal (CHUM): Propensity-Matched Study of Cost Analysis. Funding Sources: Intuitive Surgical Inc. Intuitive Foundation Clinical Research Grant Program. Total Funding - 45,000 Funding Competitive?: Yes
2018/7 - 2022/6 Principal Applicant	Obturation par système de ligature thermo-fusion de l'artère pulmonaire dans les lobectomies par vidéothoroscopie. "From Bench to Bedside". Funding Sources: Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers cliniciens - Junior 2 Total Funding - 106,179 Funding Competitive?: Yes
2022/6 - 2022/6 Co-applicant	Sensibilisation and costs analysis of surgery - Operating room Assistant - FSISSS Funding Sources: FSISSS FSISSS Total Funding - 478,105 Funding Competitive?: Yes

2022/1 - 2022/1 Principal Applicant	Endoscopic Sleeve Gastrectomy (ESG) Funding Sources: Axelys INNOVATIONS D'AVENIR Total Funding - 629,715 Funding Competitive?: Yes
2022/1 - 2022/1 Principal Applicant	Sting-Mark Device Funding Sources: Axelys INNOVATIONS D'AVENIR Total Funding - 620,326 Funding Competitive?: Yes
2016/1 - 2021/3 Principal Applicant	Prospective, Multi-Center, International Phase 2 Trial of the use of Ultrasonic Energy for Pulmonary Artery Branch Sealing during VATS Lobectomy and Cost Effectiveness Study Funding Sources: Johnson & Johnson (Ethicon) Investigator Initiated Study Total Funding - 1,807,455 Funding Competitive?: Yes
2021/1 - 2021/1 Collaborator	Combining Camu-Camu prebiotics and anti-PD-1 to improve gut microbiome and clinical outcomes for patients with non-small cell lung cancer - The W. Garfield Weston Foundation - Weston Family Microbiome Initiative Grant Funding Sources: The W. Garfield Weston Foundation Weston Family Microbiome Initiative Total Funding - 146,000 Funding Competitive?: Yes
2017/1 - 2020/12 Principal Applicant	Image-Guided Endoscopic Diagnostics and Therapeutics Funding Sources: Gosselin Foundation, Canada Equipement and Infrastructure Grant Total Funding - 1,050,000 Funding Competitive?: Yes
Under Review [n=1]	
2020/9 - 2024/9 Co-applicant	Multi MODal Research program for Personalized oncology beyond Genomics (MMORPG) Funding Sources: Canadian Foundation for Innovation Innovation Fund 2020 Total Funding - 5,018,819 Funding Competitive?: Yes

Publications

Journal Articles

1. Huseini T, DeMaio A, Yarmus L, Pollock C, Katz A, Nasir B, Majid A, Soder S, Liberman M. (2024). The Impact of Balloon Use During Endobronchial Ultrasound: A Randomized Pilot Study. *Respiration*. -(-): 1-9. Published
2. Li Q, Lafrance D, Liberman M, Leduc C, Charbonney E, Titova P, Manganas H, Chasse M. (2024). Transbronchial lung cryobiopsies, transbronchial forceps lung biopsies and surgical lung biopsies in mechanically ventilated patients with acute hypoxemic respiratory failure: a retrospective cohort study. *Journal of Intensive Care Medicine*. Online(0): 0. Accepted
3. Leong T, Smithers BM, Michael M, Haustermans K, Wong R, GebSKI V, O'Connell RL, Zalcbberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. (2024). Preoperative Chemoradiotherapy for Resectable Gastric Cancer. *The New England Journal of Medicine*. 391(19): 1810-1821. Published
4. *Têtu M, *Guimarães Rocha Lima P, *Castano W, *Bulgarelli Maqueda L, Ferraro P, Nasir B, Liberman M. (2024). Outside the Cage (OTC) Non-Intercostal Robotic Assisted Esophagectomy. *Annals of Thoracic Surgery Short Reports*. 0: 0. In Press
5. Liberman M, Markel T, Morgenthal C, Leung S, Nakeeb A, Shakir F, Yasafuku K, Curtis N, Sundaram CP, Canavan K, Veldhuis P, Atiyani O. (2024). Efficacy and Usability of an Ultrasonic Sealing Device in the Pediatric and Adult Population: A Prospective Evaluation. *Journal of Medical - Clinical Research & Reviews*. 8(12): 1-9. Published
6. Huang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Evans N, Donahoe L, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M, Luketich J, Pennathur A, Petersen G, Ripley R, Rochefort M, Seder CW, Shrager J, Su S, Tong B, Shargall Y, Vaporciyan A, Waddell T, Weksler B, Wigle D, Yendamuri S, Jones DR. (2024). Initial Patient Characteristics of TSOG 102: A Multicenter Prospective Registry of Active Surveillance in Patients with Multiple Ground Glass Opacities. *The Journal of Thoracic and Cardiovascular Surgery*. S0022-5223(24): 00910-3. In Press
7. Nasir B, Weatherald J, Ramsay T, Cypel M, Donahoe L, Durkin C, Schisler T, Nagendran J, Liberman M, Landry C, Overbeek C, Moore A, Ferraro P. (2024). Randomized Trial Of Routine Versus On-demand Intraoperative Extracorporeal Membrane Oxygenation In Lung Transplantation: A Feasibility Study. *Journal of Heart and Lung Transplantation*. S1053-2498(24): 01496-7. Published, Open Access?: Yes
8. *Lima PGR, Glorion M, Liberman M. (2024). Lobar or Sublobar Resection of Peripheral Stage I Non-Small Cell Lung Cancer. *Current Opinion in Pulmonary Medicine*. 30(4): 352-358. Published
9. Desilets A, Pinheir G, Belkaid W, Salko O, Malob J, Zarour E, Jouquan A, Thibaudeau A-J, Nolin M-A, Stagg J, Marie Florescu M, Tehfe M, Blais N, Tabchi S, Chalaoui J, Stephenson P, Ikrief A, Quoc-Huy Trinh V, Routy B, Liberman M. (2024). CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC. *JTO Clinical and Research Reports*. 5(12): 100737. Published

- [10.](#) Dunne EG, Fick CN, Isbell JM, Chaft JE, Altorki N, Park BJ, Spicer J, Forde PM, Gomez D, Iyengar P, Harpole DH Jr, Stinchcombe TE, Liberman M, Bott MJ, Adusumilli PS, Huang J, Rocco G, Jones DR. (2024). The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. *The Annals of Thoracic Surgery*. 118(1): 119-129.
Published
11. Garassino M, Gao S, Liberman M, Spicer J, Chen K-N, Vanakesa T, Thiberville L, Chaves F, Liu G, Okada M, Saji H, Laktionov K, Rittmeyer A, Bosch-Barrera J, Gentzler RD, Ganti AK, Jensen E, Keller SM, Samkari A, Wakelee H. (2024). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage NSCL cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*. 404(10459): 1240-1252.
Published
- [12.](#) Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. (2024). Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 42(10): 1110-1113.
Published
13. Shojaee S, Maldonado F, Grosu HB, Desai A, Kolli P, Bishay V, Chick J, Yasufuku K, Reisenauer J, Ferguson M, Kaufman A, Decamp MM, Mehta R, Feller-Kopman DJ, Lee G, Bedawi E, Rahman N, Gesthalter Y, Lentz RJ, Liberman M, Nadolski G, Davis H, Ghori UK, Gillaspie E, Chaddha U. (2024). Multidisciplinary Management of Adult Patients with Chylothorax: A Consensus Statement. *European Respiratory Journal*. 0: 0.
Accepted
- [14.](#) Menezes V, Pollock C, Ferraro P, Nasir B, Leduc C, Morisset J, Liberman M. (2024). Menezes V, Pollock C, Ferraro P, Nasir B, Leduc C, Morisset J, Liberman M. Defining Optimal Settings for Lung Cryobiopsy in End-Stage Pulmonary Disease. A Human, Ex Vivo, Diseased Lung Clinical Trial. *J Bronchology Interv Pulmonol*. 31(2): 188-198.
Published
- [15.](#) Menezes V, Pollock C, Ferraro P, Nasir B, Leduc C, Morisset J, Liberman M. (2024). Defining Optimal Settings for Lung Cryobiopsy in End-Stage Pulmonary Disease. A Human, Ex Vivo, Diseased Lung Clinical Trial. *J Bronchology Interv Pulmonol*. 31(2): 188-198.
Published
16. Fortin M, Liberman M, Delage A, Dion G, Martel S, Rolland F, Soumagne T, Trahan S, Assayag D, Albert E, Kelly MM, Johansson KA, Guenther Z, Leduc C, Manganas H, Prevonault J, Provence S. (2023). Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy: A Prospective Multi-Centre Agreement Clinical Trial (CAN-ICE). *American Journal of Respiratory and Critical Care Medicine*. 207: 1612-1619.
17. Chaudry F, Thiverge-Southidara M, Molina JC, Farooqui S, Hussain ST, Liberman M. (2023). CT-Guided vs. Navigational Bronchoscopic Biopsies for Solitary Pulmonary Nodules: A Single-Institution Retrospective Comparison. *Cancers*. 15: 5258.
18. Bulgarelli Maqueda L, Têtu M, Guimarães Rocha Lima P, Abu-Reida F, Alashgar O, Dayan G, Nasir B, Ferraro P, Liberman M. (2023). Outside the Cage (OTC) Subcostal RATS Lobectomy, Technical Aspects and Results of the First Series of a Novel Approach to Pulmonary Lobectomy. *Innovations*. 18(6): 519-524.
Published
19. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes EE. (2023). Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. *New England Journal of Medicine*. 388: 489-498.

20. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. (2023). **Lobar or sublobar resection of peripheral stage I non-small cell lung cancer**. The New England Journal of Medicine. 388(6): 489-498.
Published
21. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M.M. Felip E, Broderick SE, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu T-E, Saylor GB, Tanaka F, Ito H, Chen K-N, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. (2023). Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer. Future Oncology. 19: 549-557.
22. Diallo E-H., Brouillard P, Raymond J -M., Liberman M, Duceppe E, Potter BJ. (2023). Predictors and impact of postoperative atrial fibrillation following thoracic surgery: a state-of-the-art review. Anaesthesia. 78: 491-500.
23. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooks C, Majem M, Eigendorff E, Martinengo G. L., Bylicki O, Rodríguez-Abreu D, Chaft J.E., Novello S, Yang J, Keller S.M., Samkari A, Spicer J. (2023). Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. New England Journal of Medicine. 389: 491-503.
24. Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. (2023). Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 167(1): 338-347.
Published
- [25.](#) Lococo F, Nachira D, Chiappetta M, Evangelista J, Falcoz P.E, Ruffini E, Van Schil P, Scarci M, Furàk J, Sollitto F, Guerrera F, Spaggiari L, Aigner C, Evangelia L, Billè A, Moser B, Thomas PA, Liberman M, Boubia S, Campisi A, Ampolini L, Toker A, Enyed A, Voltolini L, Van Raemdonck L, Margaritora S, ESTS Thymic Working Group. (2022). Does Myasthenia Gravis Affect Long-Term Survival in Thymic Carcinomas? An ESTS Database Analysis. Diagnostics. 12(7): 1794.
Published
26. Chaddha U, Agrawal A, Feller-Kopman D, Kaul V, Shojaaee S, Maldonado F, Ferguson MK, Blyth KG, Grosu HB, Corcoran JP, Sachdeva A, West A, Bedawi EO, Majid A, Mehta RM, Folch E, Liberman M, Wahidi MM, Gangadharan SP, Roberts ME, DeCamp MM, Rahman NM. (2021). Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. The Lancet Respiratory Medicine. 9: 1050-1064.
27. Molina JC, *Goudie E, *Pollock C, *Menezes V, Ferraro P, Lafontaine E, Martin J, Liberman M. (2021). Balloon Dilation for Endosonographic Staging in Esophageal Cancer: A Phase 1 Clinical Trial. The Annals of Thoracic Surgery. 111: 1150-1155.
Published
28. Maldonado F, Danoff S, Wells A, Colby T, Ryu J, Liberman M, Wahidi M, Frazer-green L, Hetzel J, Rickman O, Herth F, Poletti V, Yarmus L. (2020). Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases. CHEST. 157: 1030-1042.
Submitted
29. Goudie E, Liberman M. (2020). Ultrasonic Shears for Pulmonary Artery Sealing in Minimally Invasive Anatomical Lung Resections. WABIP. 7: 1.
Published
30. Soder S, Liberman M. (2020). The surprise is gone! Far beyond surgical instinct – the power of information. Journal of Thoracic and Cardiovascular Surgery Techniques. 4: 321-322.
Published

31. Tahiri M, Goudie E, Jouquan A, Martin J, Ferraro P, Liberman M. (2020). Enhanced recovery after video-assisted thoracoscopic surgery lobectomy: a prospective, historically controlled, propensity-matched clinical study. *Canadian Journal of Surgery*. 63: e233-e240.
Published
32. Liberman M, *Goudie E, Morse C. (2020). Prospective, multicenter, international phase 2 trial evaluating ultrasonic energy for pulmonary artery branch sealing in video-assisted thoracoscopic surgery lobectomy. *Journal of Thoracic and Cardiovascular Surgery*. 159: 301-311.
Published
33. Liberman M. (2020). Diseases of the Esophagus. *ISDE Presidential Biography: Duranceau*. 33:doz115: 115.
Published
34. Goudie E, Ferraro P, Lafontaine E, Martin J, Liberman M. (2020). Heat production during pulmonary artery sealing with energy vessel-sealing devices in a swine model. *Interactive Cardiovascular and Thoracic Surgery*. 31: 847-852.
Published
35. Fortin M, Yarmus L, Rendina E, R Andrade, Michaud G, J Kazakov, Arias S, R Orrtiz, Liberman M . (2020). Multi-Institutional Retrospective Analysis of Adverse Events Following Rigid Tracheo-Bronchoscopy. *Respirology*. 26: 87-91.
Published
36. Liberman M. (2020). There is no “I” in team. Regionalization in thoracic surgery, the interdependence of the team, and surgical volume. *Journal of Thoracic and Cardiovascular Surgery*. 161: 330-331.
In Press
37. *Menezes VC, Liberman M. (2020). Mediastinal restaging with endosonography—Encouraging results, but does it really matter?. *Journal of Thoracic and Cardiovascular Surgery*. 159: 1109-1110.
Published
38. Nasir BS, Landry C, Menaouar A, Germain JF, Der Sarkissian S, Stevens LM, Aceros H, Cailhier JF, Leduc C, Liberman M, Noiseux N, Ferraro P. (2020). Inhibitor Improves Lung Protection in Porcine Model of Donation after Circulatory Arrest. *Annals of Thoracic Surgery*. 110: 1861-1868.
In Press
39. Gilbert CR, Wahidi MM, Light RW, Rivera MP, Sterman DH, Thomas R, Shojaee S, Shoham S, Psallidas I, Ost DE, Molena D, Maskell N, Maldonado F, Liberman M, Lee YCG, Lee H, Herth FJF, Grosu H, Gorden JA, Fysh ETH, Corcoran JP, Argento AC, Akulian JA, Rahman NM, Yarmus LB; Interventional Pulmonary Outcomes Group. (2020). Management of Indwelling Tunneled Pleural Catheters: A Modified Delphi Consensus Statement. *Chest*. 158(5): 2221-2228.
In Press
- [40.](#) Nasir BS, Landry C, Menaouar A, Germain JF, Der Sarkissian S, Stevens LM, Aceros H, Cailhier JF, Leduc C, Liberman M, Noiseux N, Ferraro P. (2020). HSP90 Inhibitor Improves Lung Protection in Porcine Model of Donation After Circulatory Arrest. *The Annals of Thoracic Surgery*. 110(6): 1861-1868.
Published
41. Molina JC, Chaudry F, Menezes V, Ferraro P, Lafontaine E, Martin J, Nasir B, Liberman M . (2020). Transvascular endosonographic-guided needle biopsy of intrathoracic lesions. *Journal of Thoracic and Cardiovascular Surgery*. 159: 2057-2065.
Submitted
42. *Hegde P, Molina JC, Thiverge-Southidara M, Jain VR, Gowda A, Ferraro P, Liberman M. (2020). Combined Endosonographic Mediastinal Lymph Node Staging in Positron Emission Tomography and Computed Tomography Node-Negative Non-Small-Cell Lung Cancer in High-Risk Patients. *Seminars in Thoracic Cardiovascular Surgery*. 32: 162-168.
Published

43. Maldondo F, Wells A, Danoff S, Colby T, Ryu J, Poletti V, Rickman O, Herth F, Wahidi M, Hetzel J, Liberman M, Yarmus L. (2019). Before Freezing Out Cryobiopsy, We Need to Thaw Out Flaws in theDiagnosis of Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*. 200: 937-938.
Published
44. Ben Ali W, Liberman M, Perrault LP. (2019). Prehabilitation for increasing ventilatory efficiency before lungresection: Amazing concept, but we're not there yet!. *Journal of Thoracic and Cardiovascular Surgery*. 157: 2513-2514.
Published
45. Molina JC, Liberman M. (2019). Pulling an entire lung out of a small incision-Video-assistedthoracoscopic surgical pneumonectomy, the final frontier in minimally invasivethoracic surgery. *Journal of Thoracic and Cardiovascular Surgery*. 158: 267-268.
Published
46. Ho C, Lefresne S, Liberman M, McGuire A, Palma D, Pender A, Snow S, Tremblay A, Myers R. (2019). Lung Cancer in Canada. *Journal of Thoracic Oncology*. 14: 1128–1133.
47. Godin A, *Molina JC, Morisset J, Liberman M. (2019). The future of surgical lung biopsy: moving from the operating room tothe bronchoscopy suite. *Current Challenges in Thoracic Surgery*. 1: 23.
48. Pressacco J, Thomas-Gittens J, Charest M Bitton, Y, Rousseau M, Liberman M. (2019). Preoperative Imaging of a Malignant Cardiac Tumor. *Annals of Thoracic Surgery*. 107: e141.
49. Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. (2018). Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). *The Lancet Respiratory Medicine*. 6: 915-924.
50. Nasir B, Yasufuku K, Liberman M. (2018). When should negative EBUS findings be confirmed by a more invasive procedure?. *Annals of Surgical Oncology*. 25: 68-75.
In Press
51. Hegde P, * Goudie E, Liberman M . (2018). Endosonographic lymph node staging by combined Endobronchial Ultrasound (EBUS) and Endoscopic Ultrasound: Technique and Technical Tricks. *Operative Techniques in Thoracic and Cardiovascular Surgery*. 23: 136-150.
Published
52. Frechette B, Thiffault V, Ferraro P, Liberman M. (2018). Diagnostic Accuracy of Mediastinal Lymph Node Staging Techniques in the Pre-Operative Assessment of Non-Small Cell Lung Cancer Patients. *J Bronchology*. 25(1): 17-24.
In Press
53. Menaouar A, Landry C, Germain J, Cailhier J, Noiseux N, Laplante P, Der Sarkissian S, Liberman M, Berthiaume Y, Ferraro P. (2018). Porcine Model of Sepsis-Induced Systemic Inflammation and Acute Lung Injury: Can Injured Lungs be Recovered with EVLP alone?. *The Journal of Heart and Lung Transplantation*. 37: S228-S229.
Published
54. Pais FM, Shah RA, Vempilly JJ, Gullapalli S, Udaphyay D, Peterson M, Liberman M, Hegde P. (2018). Transesophageal approach to lung, adrenal biopsy and fiducial placement using endoscopic ultrasonography (EUS): An interventional pulmonology experience. Initial experience of the UCSF-FRETOC (fresno tracheobronchial & oesophageal center). *Respiratory Medicine*. 141: 52-55.
55. Chaput-Dugas ME, Chughtai T, Liberman M, Duranceau A, Martin J, Barkat F, Ferraro P. (2018). Successful Resection of a Large Incidentally Found Primary Mediastinal Liposarcoma. *JSCR*. 8: 1.
Published

56. Goudie E, Thiffault V, Jouquan A, Lafontaine E, Ferraro P, Liberman M. (2018). Phase 1 Trial Evaluating Safety of Pulmonary Artery Sealing with Ultrasonic Energy in VATS Lobectomy. *Annals of Thoracic Surgery*. 105(1): 214-220.
In Press
57. Liberman M. (2018). If your hospital has RATS, do not exterminate. *Journal of Thoracic and Cardiovascular Surgery*. 155: 777-777.
Published

Book Chapters

1. Liberman M, Castano Ruiz W. (2024). Is tPA/DNase effective routine initial therapy for pleural empyema?. Mark K. Ferguson. *Difficult Decisions in Thoracic Surgery: An Evidence-Based Approach*. 5th
Accepted, Springer Nature, United States of America
2. Liberman, M. (2022). *Surgical Treatment of Esophageal Perforation*. Hawn, Mary T. *Operative Techniques in Surgery*. 2nd
Published, Wolters Kluwer Health, United States of America
3. Soder S, Liberman M. (2021). Thymectomy in the setting of pleural metastasis. Ferguson, Mark K. *Difficult Decisions in Thoracic Surgery*. 4
Published, Springer Cham, United States of America
4. Liberman M. (2020). *Esophageal Surgery at the University of Montreal*. Deslauriers, J. *Evolution of Thoracic Surgery in Canada*.
Published, Decker Intellectual Properties, Canada
5. Liberman M. (2020). *Technique for management of esophageal perforations: Cervical, Thoracic and Abdominal*. Hawn, Mary T. *Operative Techniques in Surgery*.
Published, Lippincott Williams & Wilkins, United States of America
6. Soder S*, Liberman M. (2020). *Difficult Decisions in Thoracic Surgery*. Ferguson, Mark K. *Thymectomy in the setting of pleural metastasis*. 4th edition
Published, Springer Link, United States of America
7. Molina JC*, Liberman M. (2020). *Complications of Esophageal Surgery*. Sugarbaker, David J. *Adult Chest Surgery*. 3rd edition
Published, David Sugarbaker et al., United States of America
8. Liberman M, Kazakov J. (2020). *Pleurodesis / Pleur-X*. Mathisen DJ, Morse CR. *Master Techniques in Thoracic Surgery*.
Published, Lippincott Williams & Wilkins, United States of America
9. *Hegde P, Liberman M. (2020). *Current Controversies in Thoracic Surgery*. Ambroggi V, Tomasso CM. *Thoracic Surgical Clinics*.
Published, Elsevier, United States of America
10. Liberman M. (2020). *Endoscopic Myotomy for Achalasia*. Deslauriers J. *Evolution of Thoracic Surgery in Canada*.
Published, Decker Intellectual Properties, Canada
11. Liberman M, Nasir B. (2020). *Preoperative chemo vs chemoradiotherapy for regionally advanced esophageal adenocarcinoma*. Ferguson M. K. *Difficult Decisions in Thoracic Surgery*.
Published, Springer Link, United States of America
12. Liberman M, Goudie E. (2020). *Cervical Video Assisted Thoracic Surgery*. Zielinski M, Rami-Porta R. *The Transcervical Approach in Thoracic Surgery*.
Published, Springer, United States of America

13. Liberman M, Nasir B. (2018). Ultrasound and Endoscopic Bronchoscopic Ultrasound in the Evaluation of the Lungs, Mediastinum, and Pleura. LoCicero III J. Shield's General Thoracic Surgery. 8th Published, Wolters Kluwer Health, United States of America

Conference Publications

1. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: results from CALGB 140503 (Alliance). AATS 105th Annual Meeting, New York, United States of America
Conference Date: 2025/5
Abstract
2. Glorion M, Noly P, Menaouar A, Roquebert L, Pizzi S, Borie M, Kamel L, Tumusengue C, Landry C, Lucien T, Liberman M, Nasir B, Ferraro P, Noiseux N. Warm Ischemia Time and Unsuccessful Heart Resuscitation with TA-NRP May Negatively Affect Lung Function in a Preclinical DCD Model. ISHLT 2025, Boston, United States of America
Conference Date: 2025/4
Abstract
3. Wakelee H, Spicer J, Liberman M, Gao S, Deng X, Keller S. Perioperative Pembrolizumab for Early-Stage NSCLC: Japanese Subgroup of KEYNOTE-671. 65th Annual Meeting of the Japan Lung Cancer Society, JLCS 2024, Yokohama, Japan
Conference Date: 2024/11
Abstract
4. Provencio M, Spicer JD, Girard Nm Wang C, Mitsudomi T, Awad MM, Vokes EE, Taube JM, Lupinacci L, Saylors GB, Tanaka F, Liberman M, Lee SY, Alexandru A, D'Arcangelo M, Tran P, Gharpure V, Bhingare A, Forde PM. Neoadjuvant nivolumab + chemotherapy vs chemotherapy in patients with resectable stage II–IIIA NSCLC and tumor PD-L1 $\geq 1\%$: 4-year update from Checkmate 816. XII Educational Symposium of the Spanish Lung Cancer Group, Madrid, Spain
Conference Date: 2024/11
Abstract
5. Jones D, Wakelee H, Spicer J, Liberman M, Kato T, Tsuboi M, Lee S-H, Wang W. X, Chen K-N, Doms C, Majem M, Eigendorff E, Martinengo G. Bylicki O, Chuang H, Novello S, Khator N, Jensen E, Keller S, Samkari A. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. IASLC 2024 World Conference on Lung Cancer (WCLC 2024), San Diego, United States of America
Conference Date: 2024/9
Abstract
6. Janjigian YY, Al-Batran S-E, Wainberg Z, Van Cutsem E, Molena D, Muro K, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira S, Liberman M, Oriden VC, Bilici M, Kurland JF Xynos I, Mann H, Tabernero J. Pathological complete response to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel plus or minus durvalumab in resectable gastric and gastroesophageal junction cancer: MATTERHORN subgroup results. International Thoracic Surgical Oncology Summit 2024 (AATS), New York, United States of America
Conference Date: 2024/9
Abstract
7. *Guimañes Rocha Lima P, Liberman M. Intra- and Post-Operative Endoscopic Evaluation of the Esophageal Anastomosis During and After Esophagectomy. International Thoracic Surgical Oncology Summit 2024 (AATS), New York, United States of America
Conference Date: 2024/9
Poster

8. Garassino M, Gao S, Liberman M, Spicer J, Chen K-N, Vanakesa T, Thiberville L, Chaves F, Liu G, Okada M, Saji H, Laktionov K, Rittmeyer A, Bosch-Barrera J, Gentzler RD, Ganti AK, Jensen E, Keller SM, Samkari A, Wakelee H. Neoadjuvant Pembrolizumab (pembro) or Placebo (pbo) Plus Chemotherapy and Adjuvant Pembro or Pbo for Early-Stage NSCLC: Subgroup Analyses of the Phase 3 KEYNOTE-671 Study. European Society for Medical Oncology 2024 Congress (ESMO 2024), Barcelona, Spain
Conference Date: 2024/9
Poster
9. Cascone T, Guisier F, Bonanno L, Liberman M, Bylicki O, Insa A, Forde P, Bielska A, Kumar R, Dowson A, Egenod T, He Y, Livi L, McGrath L, Grenga I, Corre R, Yohannes A, Mager R, Spicer JD. Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC. IASLC 2024 World Conference on Lung Cancer (WCLC 2024), San Diego, United States of America
Conference Date: 2024/9
Abstract
10. Guimañes Rocha Lima P, Liberman M. FIRST IN HUMAN, SINGLE CENTER, EARLY EXPERIENCE WITH ROBOTIC BRONCHOSCOPIC MICROWAVE ABLATION. INITIAL SHORT AND LONG TERM RESULTS FROM A PHASE 1 CLINICAL TRIAL. 2024 AABIP Annual Conference, Charlotte, United States of America
Conference Date: 2024/8
Abstract
11. *Guimañes Rocha Lima P, Liberman M. 12 Year Experience With Trans-Esophageal Pulmonary Nodule Biopsy Using Endoscopic Ultrasound. 2024 AABIP Annual Conference, Charlotte, United States of America
Conference Date: 2024/8
Abstract
12. *Guimañes Rocha Lima P, Liberman M. Endosonography-Guided Transvascular Needle Aspiration Of Thoracic Lesions: 12 Year Experience From A High-Volume Center. 2024 AABIP Annual Conference, Charlotte, United States of America
Conference Date: 2024/8
Abstract
13. Bodei L, Kavan P, Liberman M, Taunk N, Metser U, Juneau D, O'Reilly EM, Ma J, Cioci R, Abdul Razak AR. FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors. SNMMI 2024 Annual Meeting, Toronto, Canada
Conference Date: 2024/6
Abstract
14. Garassino M, Wakelee H, Spicer J, Liberman M, Kato T, Tsuboi M, Lee S-H, Chen K-N, Doms C, Majem M, Eigendorff E, Martinengo G, Bylicki O, Rodríguez-Abreu D, Chaft JE, Yang J, Arunachalam A, Norquist J, Keller S, Gao S. Health-Related Quality of Life Outcomes From the Randomized, Double-Blind Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. ASCO Annual Meeting 2024, Chicago, United States of America
Conference Date: 2024/5
Abstract
15. Spicer JD, Girard N, Pulla MP, Wang C, Mitsudomi T, Awad MM, Vokes EE, Taube JM, Lupinacci L, Saylor GB, Tanaka F, Liberman M, Lee SY, Alexandru A, D'Arcangelo M, Tran P, Mahmood J, Gharpure V, Bhingare A, Forde PM. Neoadjuvant nivolumab plus chemotherapy vs chemotherapy in patients with resectable NSCLC: 4-year update from CheckMate 816. ASCO Annual Meeting 2024, Chicago, United States of America
Conference Date: 2024/5
Abstract

16. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD, KEYNOTE-671 Investigators. Impact of Surgical Factors on EFS in the Phase 3 KEYNOTE-671 Trial of Perioperative Pembrolizumab For Early-Stage Non-Small-Cell Lung Cancer. 41st Annual Meeting of the Japanese Association for Chest Surgery, Tokyo, Japan
Conference Date: 2024/5
Abstract
17. BMS Thoracic Team, Liberman M. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. ASCO Annual Meeting 2024, Chicago, United States of America
Conference Date: 2024/5
Abstract
18. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD, KEYNOTE-671 Investigators. Impact of Surgical Factors on Event-Free Survival in the Randomized, Placebo-Controlled, Phase 3 KEYNOTE-671 Trial of Perioperative Pembrolizumab For Early-Stage Non-Small-Cell Lung Cancer (NSCLC). ESTS 2024, Barcelona, Spain
Conference Date: 2024/5
Abstract
19. Janjigian Y.Y., Al-Batran S-E., Wainberg Z.A., Van Cutsem E, Molena D, Muro K, Hyung W.J., Wyrwicz L.S., Oh D-Y, Omori T, Moehler M, Garrido M, Cunha Sousa Oliveira S, Liberman M, Castro Oliden V, Bilici M, Kurland J.F., Xynos I, Mann H, Tabernero J. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase 3 MATTERHORN study. Digestive Disease Week, Washington, D.C., United States of America
Conference Date: 2024/5
Poster
20. Huang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Donahoe L, Evans N, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M., Luketich J, Pennathur A, Petersen CG, Ripley T, Rochefort M, Seder C, Shargall Y. Initial Patient Characteristics in a Multi-institutional Prospective Registry Trial of Active Surveillance in Patients with Multiple Ground Glass Opacities (TSOG 102). AATS 104th Annual Meeting, Toronto, Canada
Conference Date: 2024/4
Abstract
21. Spicer J, Liberman M, BMS Thoracic Team. 3-year Health-Related Quality of Life (HRQoL) Outcomes With Neoadjuvant Nivolumab (NIVO) + Chemotherapy (Chemo) for Resectable NSCLC in CheckMate 816. AATS Annual Meeting 2024, Toronto, Canada
Conference Date: 2024/4
Abstract
22. Miller D, Liberman M. Postoperative Complications Compromised Disease-free and Recurrence-free Survival in CALGB 140503 Trial Patients. AATS 104th Meeting, Toronto, Canada
Conference Date: 2024/4
Abstract
23. Guimães Rocha Lima P, Liberman M. First In Human, Single Center, Early Experience with Robotic Bronchoscopic Microwave Ablation - Initial Short and Long Term Results from a Phase 1 Clinical Trial. AATS 104th Annual Meeting, Toronto, Canada
Conference Date: 2024/4
Abstract

24. Janjigian YY, Al-Batran S-E, Wainberg Z, Van Cutsem E, Molena D, Muro K, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira S, Liberman M, Oliden VC, Bilici M, Kurland JF Xynos I, Mann H, Tabernero J. Pathological complete response to FLOT chemotherapy with or without durvalumab in resectable gastric and gastroesophageal junction cancer: subgroup analysis by region from the Phase 3, randomized, double-blind MATTERHORN study. Society of Surgical Oncology - International Conference on Surgical Cancer Care, Atlanta, United States of America
Conference Date: 2024/3
Abstract
25. Janjigian YY, Al-Batran S-E, Wainberg Z, Van Cutsem E, Molena D, Muro K, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira S, Liberman M, Oliden VC, Bilici M, Kurland JF Xynos I, Mann H, Tabernero J. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC). ASCO GI 2024, San Francisco, United States of America
Conference Date: 2024/1
Abstract
26. Janjigian YY, Al-Batran S-E, Wainberg Z, Van Cutsem E, Molena D, Muro K, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira S, Liberman M, Oliden VC, Bilici M, Kurland JF Xynos I, Mann H, Tabernero J. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study. ESMO 48th Congress, Madrid, Spain
Conference Date: 2023/10
Abstract

Intellectual Property

Patents

1. Radio-Opaque Marker and System for Tumourous Tissue - Sting-Mark. United States of America. 10249569-94. 2022/01/21.
Patent Status: Allowed
2. Intragastric Balloon System - Endoscopic Sleeve Gastrectomy (ESG) Balloon. United States of America. 10249569-96. 2022/01/12.
Patent Status: Allowed
3. Attachment system for endoscopes. United States of America. 3178623. 2021/05/12.
Patent Status: Allowed
Year Issued: 2021
Year of End Term: 2041

Presentations

1. (2024). Long-term Health-related Quality of Life (HRQoL) Outcomes With Neoadjuvant Nivolumab (NIVO) + Chemotherapy (Chemo) for Resectable NSCLC in CheckMate 816.AATS 104th Annual Meeting, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
2. (2024). Preoperative Inspiratory Muscle Training Program Based on Breathing Exercises with Incentive Spirometry to Prevent Postoperative Pulmonary Complications in Thoracic Surgery:A Randomized Clinical Trial. AATS 104th Annual Meeting, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

3. (2023). The randomized, double-blind, phase 3 KEYNOTE-671 study of neoadjuvant pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and adjuvant pembrolizumab or placebo for early-stage NSCLC. AATS ITSOS Keynote Presentation., United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
4. (2023). Evolving Technologies in Thoracic Surgery: From Bench to Bedside. Thoracic Surgery Symposium, Canada
Main Audience: Researcher
Invited?: No, Keynote?: No
5. (2023). Feasibility and Safety of Outside the Cage (OTC) Subcostal Robotic Anatomical Lung Resections; Results of a Phase I Clinical Trial. International Thoracic Surgical Oncology Summit, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

Student/Postdoctoral Supervision

Master's Thesis [n=4]

2024/4 Principal Supervisor	Arman Sarshoghi, Université de Montréal Thesis/Project Title: Développement d'un protocole de cryoablation transbronchique pour le cancer du poumon : une approche combinant culture cellulaire tridimensionnelle et chirurgie expérimentale Present Position: Student
2023/8 - 2025/5 Principal Supervisor	Maxime Têtu, University of Montreal Thesis/Project Title: Cryoablation d'adénocarcinomes pulmonaires à prédominance lépidique par voie transbronchique Present Position: MSc Student
2020/8 - 2022/5 Co-Supervisor	Geneviève Chartrand, University of Montreal Thesis/Project Title: Novel Hernia Mesh Creation Present Position: Research Associate
2019/8 - 2022/5 Principal Supervisor	Anny Godin, University of Montreal Thesis/Project Title: Programme préopératoire d'entraînement musculaire inspiratoire pour prévenir les complications respiratoires après une chirurgie pulmonaire Present Position: MSc Student

Doctorate [n=1]

2024/9 Co-Supervisor	Mark Vartazamian, Polytechnique Montréal Thesis/Project Title: Optimizing Staple Design for Surgical Procedures Present Position: Engineer-Student
-------------------------	--

Post-doctorate [n=5]

2024/3 - 2026/3 Principal Supervisor	Omar Alkathiri, University of Montreal Thesis/Project Title: Fellowship in Thoracic Surgery Present Position: Fellow
2023/12 - 2023/12 Principal Supervisor	William Lee Heedo, Western University Thesis/Project Title: Endobronchial Ultrasound (EBUS) - TBNA Mentorship Present Position: MD

2023/6 - 2023/6 Principal Supervisor	Shawn Brophy, University of Calgary Thesis/Project Title: Short term observationship in Thoracic Surgery Present Position: MD
2022/11 - 2023/11 Principal Supervisor	Omniyah Alashgar, University of Montreal Thesis/Project Title: Fellowship Thoracic Surgery Present Position: Fellow
2022/6 - 2024/7 Principal Supervisor	Pedro Guimarães Rocha Lima, University of Montreal Thesis/Project Title: Fellowship Thoracic Surgery Present Position: Fellow

Date Submitted: 2025-01-07 13:37:32

Confirmation Number: 1893158

Template: CIHR Academic

Dr. Noël Raynal

Correspondence language: French

Sex: Male

Date of Birth: 9/19

Canadian Residency Status: Permanent Resident

Permanent Residency Start Date: 2006/05/11

Country of Citizenship: France

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

Département de pharmacologie et physiologie

Faculté de médecine

C. P. 6128 – Succursale Centre-ville

Université de Montréal

Montréal Quebec H3C 3J7

Canada

Telephone

Work (*) 514-345-4931 extension: 6763

Email

Personal noel_raynal@hotmail.com

Work (*) noel.raynal@umontreal.ca

Website

Community <http://recherche.chusj.org/fr/Axes-de-recherche/Bio?id=b6ebe76a-bca8-420d-ad3a-5ed8c1171ae4>



Protected when completed

Dr. Noël Raynal

Language Skills

Language	Read	Write	Speak	Understand
English	Yes	Yes	Yes	Yes
French	Yes	Yes	Yes	Yes

User Profile

Disciplines Trained In: Pharmacology

Research Disciplines: Pharmacology

Areas of Research: Cell Signaling and Cancer

Fields of Application: Biomedical Aspects of Human Health

Research Specialization Keywords: Epigenetics, Chromatin biology, DNA methylation, Epigenetic pharmacology, Preclinical drug assessment, 3D spheroid cell culture

Degrees

2011/11 - 2013/5	Post-doctorate, Post-Doc Fellow, Epigenetic pharmacology of cancer, Fels Institute for Cancer Research and Molecular Biology, Temple University, PA, USA (Dr J-P Issa) Degree Status: Completed Supervisors: Pr. Jean-Pierre J. Issa
2009/4 - 2011/11	Post-doctorate, Post-Doc Fellow, Epigenetic pharmacology of cancer, MD Anderson Cancer Cancer, University of Texas, TX, USA (Dr J-P Issa) Degree Status: Completed Supervisors: Pr. Jean-Pierre J. Issa
2008/10 - 2009/3	Post-doctorate, Post-doctoral fellow, Epigenetic pharmacology of cancer, Université de Montréal Degree Status: Completed Supervisors: Pr Richard L Momparler
2003/9 - 2008/9	Doctorate, Doctorate in Biology, Biology, INRS-Institute Armand Frappier Degree Status: Completed Supervisors: Pr. Michel Charbonneau and Pr. Richard L. Momparler
2001/1 - 2003/5	Master's Thesis, Master of Science, Biology, Université du Québec à Montréal Degree Status: Completed Supervisors: Pr. Catherine Jumarie and Pr. Alice Hontela

1997/9 - 2000/9 Bachelor's, Bachelor of Science, Biochemistry and Physiology, Université de Montpellier II (Languedoc)
Degree Status: Completed
Supervisors: Pr. Bernard Lebleu

Recognitions

2024/7 - 2028/7 Research Scholar Senior (Peer reviewed salary award) / Chercheur Boursier Senior - Volet Fondamental - 322,341 (Canadian dollar)
Fonds de recherche du Québec - Santé (FRQS)
Prize / Award

2020/7 - 2024/7 Research Scholar Junior 2 (Peer reviewed salary award) / Chercheur boursier Junior 2 - Volet Fondamental - 295,451 (Canadian dollar)
Fonds de recherche du Québec - Santé (FRQS)
Prize / Award

2020/1 - 2021/2 Award from IRICOR-Oncopole to participate to the training: Entrepreneurship training program in Life Sciences by Montréal InVivo, Université de Montréal, District 3, Concordia University, and John Molson School of Business. - 5,890 (Canadian dollar)
IRICOR-Oncopole
Prize / Award

2016/7 - 2020/7 Research Scholar Junior 1 (Peer reviewed salary award) / Chercheur boursier Junior 1 - Volet Fondamental - 256,943 (Canadian dollar)
Fonds de recherche du Québec - Santé (FRQS)
Prize / Award

2015/2 Canadian Cancer Research Alliance/CIHR New Principal Investigator Award - 400 (Canadian dollar)
Canadian Institutes of Health Research
Prize / Award

2013/10 CCSRI Junior Investigator Grant Panel Travel Award - 1,000 (Canadian dollar)
Canadian Cancer Society Research Institute
Prize / Award

2006/5 Poster presentation - 500 (Canadian dollar)
Réseau de Recherche en Santé Environnementale
Prize / Award

2005/10 - 2009/2 Armand-Frappier PhD Scholarship - 17,000 (Canadian dollar)
INRS-Institute Armand Frappier
Prize / Award

2005/3 Second best poster - 500 (United States dollar)
American Society of Toxicology Annual meeting in New Orleans, LA, carcinogenesis section
Prize / Award

2005/3 Travel award - 600 (United States dollar)
American Society of Toxicology
Prize / Award

2004/10 - 2009/2 Armand-Frappier PhD Scholarship - 14,000 (Canadian dollar)
INRS-Institute Armand Frappier
Prize / Award

2003/9 - 2009/2	Dean's Honor for academic excellence in the M.Sc. in Biology program Université du Québec à Montréal Honor
2003/3	Best poster - 250 (Canadian dollar) Canadian Network of Toxicology Centres Prize / Award
2001/11	TOXEN Scholarship - 2,000 (Canadian dollar) Université du Québec à Montréal Prize / Award

Employment

2018/7 - 2028/6	Associate Professor / Professeur sous octroi agrégé Pharmacologie et physiologie, Médecine, Université de Montréal
2015/9 - 2028/6	Director of high throughput platform of small molecules screening Axe Maladies virales, immunitaires et cancers, Centre de recherche du CHU Sainte-Justine, Université de Montréal
2015/11 - 2024/6	Co-director of epigenetics-montreal. Unité Collaborative en Épigénétique Moléculaire (epigenetics-montreal.com) Pharmacologie et physiologie, Médecine, Université de Montréal
2016/7 - 2018/6	Assistant Professor / Professeur Sous-Octroi Adjoint Pharmacologie et physiologie, Médecine, Université de Montréal
2013/7 - 2016/6	Professeur Chercheur-Adjoint Pharmacologie, Médecine, Université de Montréal

Affiliations

The primary affiliation is denoted by (*)

(*) 2018/7	Associate Professor, Faculté de Médecine, Pharmacologie et physiologie, Université de Montréal
2013/7	Principal Investigator, Centre de Recherche de l'Hôpital Sainte-Justine, Hôpital Sainte Justine

Leaves of Absence and Impact on Research

2011/9 - 2012/1	Other Circumstances, University of Texas Relocation of post-doctoral research laboratory (PI: Dr Jean-Pierre Issa) from Houston, Texas (MD ANDERSON CANCER CENTER, University of Texas) to Philadelphia, Pennsylvania (Temple University). Dates: September 2011-January 2012 (5 MONTHS)
-----------------	---

Research Funding History

Awarded [n=6]

2024/3 - 2029/3 Principal Applicant	Epigenetic priming of neuroblastoma to Natural Killer cell-based immunotherapy
--	--

Funding Sources:

2024/3 - 2029/3 Canadian Institutes of Health Research (CIHR)
Operating grant
Total Funding - 810,900 (Canadian dollar)
Funding Competitive?: Yes

2023/10 - 2028/10 Modelling cell dynamics and epigenetic changes in 3D spheroids with custom-made
Principal Investigator hydrogels. Ranked 1st/20 in Tri-Agency Interdisciplinary committee

Co-applicant : Pr Houman Savoji; Pr May Griffith; Pr Morgan Craig

Funding Sources:

2023/10 - 2028/9 Canadian Institutes of Health Research (CIHR)
Operating grant
Total Funding - 868,276 (Canadian dollar)
Funding Competitive?: Yes

2024/6 - 2026/6 New 3D preclinical models to study pediatric bone cancers and discover new therapeutic
Principal Investigator targets

Funding Sources:

2024/9 - 2025/9 Fondation Charles-Bruneau
Fonds d'Innovation Thérapeutique
Total Funding - 50,000 (Canadian dollar)
Funding Competitive?: Yes

2019/4 - 2026/4 Impact of 3D co-culture on epigenome and cell phenotype
Principal Applicant

Funding Sources:

2019/4 - 2026/4 Natural Sciences and Engineering Research Council of Canada
(NSERC)
Discovery grant
Total Funding - 256,000 (Canadian dollar)
Funding Competitive?: Yes

2022/7 - 2024/7 Genetic-based treatment adaptation in childhood patients with ALL
Co-applicant

Principal Investigator : Maja Krajinovic

Funding Sources:

2022/7 - 2024/6 Leukemia and Lymphoma Society
Operating grant
Total Funding - 197,260 (Canadian dollar)
Funding Competitive?: Yes

2023/3 - 2024/3 Epigenetic priming of neuroblastoma to NK cell-based immunotherapy
Principal Investigator Co-investigator : Elie Haddad

Funding Sources:

2023/3 - 2024/3 Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

Completed [n=13]

2023/3 - 2023/8 Research Contract with Bold Therapeutics - Combination drug screening between
Principal Investigator BOLD-100 with 1,700 FDA-approved drugs.

Funding Sources:

2020/4 - 2021/6 Bold Therapeutics
 Research contract
 Total Funding - 25,000 (Canadian dollar)
 Funding Competitive?: No

2023/3 - 2023/8 Research Contract with Bold Therapeutics-Drug screening of metallic compounds and synergistic effects.
 Principal Investigator

Funding Sources:

2023/3 - 2023/8 Bold Therapeutics
 Research contract
 Total Funding - 53,170 (Canadian dollar)
 Funding Competitive?: No

2022/7 - 2023/7 Priming neuroblastoma 3D spheroid models for NK cell-based immunotherapy
 Principal Investigator Co-investigator : Elie Haddad; Serge McGraw

Funding Sources:

2022/7 - 2023/7 CHU Sainte-Justine Research Centre
 Fondation d'innovation thérapeutique (internal funds)
 Total Funding - 50,000 (Canadian dollar)
 Funding Competitive?: Yes

2022/7 - 2023/7 Modeling tumour microenvironment acidosis and hypoxia using 3D spheroids of non-small cell lung cancer and their impact on anticancer drug effects.
 Principal Investigator

Co-investigator : Anne Lenferink; Evelyn Teh; Nazanin Larijani Rohani

Funding Sources:

2022/7 - 2023/4 NRC-CHU Sainte-Justine Collaborative Unit (CUTR).
 Operating grant
 Total Funding - 35,000 (Canadian dollar)
 Funding Competitive?: Yes

2022/7 - 2022/12 3D scaffolds for organoid growth in cancer drug discovery
 Principal Investigator Co-investigator : Houman Savoji

Funding Sources:

2022/7 - 2023/4 Institut TransMedTech
 Validation program
 Total Funding - 25,000 (Canadian dollar)
 Funding Competitive?: Yes

2022/1 - 2022/8 Research contract with Biochrom Inc for Combination drug screening with monoclonal antibodies.
 Principal Investigator

Funding Sources:

2022/1 - 2022/8 Biochrom Inc
 Research contract
 Total Funding - 11,365 (Canadian dollar)
 Funding Competitive?: Yes

2020/7 - 2021/10 Modeling tumor microenvironment acidosis and hypoxia using 3D spheroids of non-small cell lung cancer and their impact on anticancer drug effects.
 Principal Applicant

Co-investigator : Anne Lenferink; Nazanin Larijani Rohani

Funding Sources:

2020/7 - 2021/4 NRC-CHU Sainte-Justine Collaborative Unit (CUTR).
Collaborative Unit in Translational Research (CUTR)
Total Funding - 29,000 (Canadian dollar)
Funding Competitive?: Yes

2021/9 - 2021/9
Co-applicant

Sound-Induced 3D Biofabrication and Morphogenesis

Co-applicant : Nicolas Dumont;

Principal Investigator : Houman Savoji

Funding Sources:

2022/3 - 2022/4 Natural Sciences and Engineering Research Council of Canada
(NSERC)
Research Tools and Instruments
Total Funding - 128,240 (Canadian dollar)
Funding Competitive?: Yes

2015/6 - 2021/6
Principal Investigator

Toward the cure of neuroblastoma: innovative immunotherapeutic approaches.

Principal Investigator : Elie Haddad; M Duval (nominated PI)

Funding Sources:

2015/1 - 2020/6 Canadian Institutes of Health Research (CIHR)
Cancer
Total Funding - 1,050,000 (Canadian dollar)
Funding Competitive?: Yes

2020/4 - 2021/4
Principal Investigator

Plateforme de criblage de molécules in vitro avec sphéroïdes de cellules cancéreuses
arrimée à une entreprise en intelligence artificielle.

Funding Sources:

2020/4 - 2021/4 Programme Partenariat-UdeM : Soutien aux initiatives avec les
entreprises privées.
Operating grant
Total Funding - 200,000 (Canadian dollar)
Funding Competitive?: Yes

2020/10 - 2021/3
Principal Applicant

4D spheroids identify type I protein arginine methyltransferases as a target in NSCLC

Co-applicant : Christian Beauséjour; Elie Haddad; Stéphane Richard;

Co-investigator : Daniel Sinnett

Funding Sources:

2020/10 - 2021/10 Canadian Institutes of Health Research (CIHR)
Bridge funding: NRF 173588
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2018/9 - 2020/9
Principal Investigator

Targeting C-MYC addiction in cancer with the repurposing of FDA-approved proscillaridin

Funding Sources:

2018/9 - 2019/9 Cancer Research Society (The)
Upcycle
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2016/7 - 2020/6

Epigenetic therapy of pediatric cancers

Principal Investigator Funding Sources:

2016/7 - 2020/6 Fonds de recherche du Québec - Santé (FRQS)
 Fonds d'installation
 Total Funding - 60,000 (Canadian dollar)
 Funding Competitive?: Yes

Student/Postdoctoral Supervision**Bachelor's [n=16]**

Principal Supervisor	Colin Lu (Completed) , Université de Montréal Student Degree Start Date: 2025/5 Project Description: Développement de sphéroïdes tridimensionnels decancer du sein triple-négatif et évaluation de leurs potentiels précliniques.
Principal Supervisor	Michelle Alvarenga (Completed) , Université de Montréal Student Degree Start Date: 2025/5 Project Description: Développement de modèles tridimensionnels de cancer du poumon et du sein et évaluation de leurs potentiels précliniques.
Principal Supervisor	Valentina Andrade Perez (Completed) , University of Bogota, Columbia Student Degree Start Date: 2024/5 Project Description: Co-culture of neuroblastoma spheroids with Natural Killer cells.
Principal Supervisor	Juba Mansouri (Completed) , Université de Montréal Student Degree Start Date: 2024/5 Project Description: Modelling celldynamics and epigenetic changes in cancer cell lines with human like plasma cell culture media
Principal Supervisor	Félix Girolamo-Cousineau (Completed) , Université de Montréal Student Degree Start Date: 2023/7 Present Position: Medical Student
Principal Supervisor	Joëlle Carrière (Completed) , Université de Montréal Student Degree Start Date: 2022/9 Present Position: Bachelor student
Principal Supervisor	Emmanuel Sy (Completed) , Université de Montréal Student Degree Start Date: 2017/9 Present Position: MSc
Principal Supervisor	Walid Mohammed Mardhy (Completed) , Université de Montréal Student Degree Start Date: 2017/9 Present Position: MSc Student
Principal Supervisor	Gabrielle McInnes (Completed) , Université de Sherbrooke Student Degree Start Date: 2017/8 Present Position: MSc
Principal Supervisor	Elisa Clément (Completed) , Université de Montréal Student Degree Start Date: 2016/9 Present Position: Bachelor student
Principal Supervisor	Alexis Métral (Completed) , Université de Montréal Student Degree Start Date: 2016/9 Present Position: Bachelor

Principal Supervisor	Yvonne Pohontu (Completed) , Université de Montréal Student Degree Start Date: 2014/9 Present Position: Scientist
Co-Supervisor	David Goldblatt (Completed) , Penn state University Student Degree Start Date: 2013/6
Principal Supervisor	Mounir Bouslimani (Completed) , Université de Sherbrooke Student Degree Start Date: 2012/9 Student Degree Received Date: 2015/5 Present Position: Clinical Coordinator
Principal Supervisor	Simon Jacques-Ricard (Completed) , Université de Montréal Student Degree Start Date: 2011/9 Student Degree Received Date: 2014/9 Present Position: Scientist
Principal Supervisor	Gregory Armaos (Completed) , Université de Montréal Student Degree Start Date: 2010/9 Student Degree Received Date: 2014/9 Present Position: Scientist

Master's Equivalent [n=1]

Principal Supervisor	Mohamed Galal Fares (Completed) , Université de Montréal Student Degree Start Date: 2024/12 Project Description: 3D neuroblastoma spheroid characterization
----------------------	---

Master's Thesis [n=13]

Principal Supervisor	Harshini Renganathan (In Progress) , Université de Montréal Student Degree Start Date: 2024/9 Project Description: Impact sur l'épigénome, le métabolisme des modèles de co-culture 3D de cancer du poumon avec des fibroblastes.
Co-Supervisor	Rahinatou Djibo (Completed) , Université de Montréal Student Degree Start Date: 2024/9 Present Position: Msc Student
Principal Supervisor	Federico Unger Granados (Completed) , Université de Montréal Student Degree Start Date: 2023/1 Student Degree Received Date: 2025/5 Project Description: Impact sur l'épigénome, le métabolisme des modèles de co-culture 3D de cancer du poumon avec des fibroblastes. Present Position: MSc student in progress
Academic Advisor	Agata Mostkowska (Completed) , Université de Montréal Student Degree Start Date: 2021/9 Student Degree Received Date: 2023/12 Present Position: MSc Student
Principal Supervisor	Walid Mohammed Mardhy (Completed) , Université de Montréal Student Degree Start Date: 2020/9 Present Position: Université de Montréal
Principal Supervisor	Emmanuel Sy (Completed) , Université de Montréal Student Degree Start Date: 2020/9 Present Position: MSc Student

Principal Supervisor	Mariya Kryvoshey (Completed) , Université de Montréal Student Degree Start Date: 2020/1 Present Position: MSc student
Principal Supervisor	Marielle Huot (Completed) , Université de Montréal Student Degree Start Date: 2019/9 Present Position: Bioinformatician
Principal Supervisor	Gabrielle McInnes (Completed) , Université de Montréal Student Degree Start Date: 2018/1 Student Degree Received Date: 2019/11 Project Description: Establishment of a spheroid model for in vitro drug screening. Present Position: MSc Student
Co-Supervisor	Virginie Bertrand-Lehouiller (Completed) , Université de Montréal Student Degree Start Date: 2016/5 Student Degree Received Date: 2018/9 Present Position: MSc Student
Principal Supervisor	Simon Jacques-Ricard (Completed) , Université de Montréal Student Degree Start Date: 2014/9 Student Degree Received Date: 2017/5 Present Position: Scientist
Principal Supervisor	Gregory Armaos (Completed) , université de Montréal Student Degree Start Date: 2014/1 Student Degree Received Date: 2016/5 Present Position: Scientist
Principal Supervisor	Catherine Thall-Dubé (Completed) , Université de Montréal Student Degree Start Date: 2013/9 Student Degree Received Date: 2014/12 Project Description: Combination of decitabine and genistein against acute pediatric leukemia. Present Position: Lawyer

Doctorate [n=5]

Co-Supervisor	Amir Aidun (In Progress) , Université de Montréal Student Degree Start Date: 2024/5 Project Description: <i>Modelling celldynamics and epigenetic changes in 3D spheroids with custom-made hydrogels</i>
Principal Supervisor	Minoo Alvani (In Progress) , Université de Montréal Student Degree Start Date: 2023/11 Student Degree Expected Date: 2028/9 Present Position: PhD Student
Co-Supervisor	Covida Mootoosamy (In Progress) , Université de Montréal Student Degree Start Date: 2022/1 Student Degree Expected Date: 2027/5 Present Position: PhD Student
Principal Supervisor	Élodie Da Costa (Completed) , Université de Montréal Student Degree Start Date: 2016/5 Student Degree Received Date: 2020/5 Present Position: PhD Student
Co-Supervisor	Appoline Kopp (Completed) , Université de Rennes Student Degree Start Date: 2015/9

Post-doctorate [n=1]

Principal Supervisor Anaïs Daracq (In Progress) , Université de Montréal
 Student Degree Start Date: 2021/1
 Project Description: Triple negative breast cancer epigenetics
 Present Position: Postdoctoral fellow

Community and Volunteer Activities

2016/9 Elected member of the Young Researcher committee, Sainte-Justine Research Center
 Identify solutions to problems of Young Researchers at Sainte-Justine Research Center.

Presentations

1. (2024). Repositionnement de médicaments pour les rhabdomyosarcomes. Conférencier invité à la Journée de réseautage québécois sur les sarcomes de l'enfant et du jeune adulte de la Fondation Dania-Kayali., Montréal, Canada
 Main Audience: Researcher
 Invited?: Yes
2. (2024). Time-dependent chromatin maturation 3D spheroids improves preclinical modeling of non-small cell lung cancer. CEEHRC 10th Annual Canadian Conference on Epigenetics, from October 1 to 4, 2024., Blue Mountains, Canada
 Main Audience: Researcher
 Invited?: Yes
3. (2023). Reprogrammation de l'épigénome durant la culture de sphéroïdes en 3D : impact sur la pharmacologie des agents anticancéreux. ACFAS -Santé du Génome, Canada
 Main Audience: Researcher
 Invited?: Yes
4. (2022). Cancer Cell Transcriptomic, Epigenomic and Pharmacological Changes in 3D Culture. Annual Meeting of the Canadian Society of Pharmacology and Therapeutics, Canada
 Main Audience: Researcher
 Invited?: Yes
5. Noël Raynal, Dre Anaïs Darracq, Rahinatou Djibo. (2022). Selective CDK9 inhibition by natural compound toyocamycin in cancer cells. Conférencier invité aux conférences de l'Axe Maladie Immunitaire et Cancer du CHU Sainte-Justine, Canada
 Main Audience: Researcher
 Invited?: Yes
6. (2022). Parcours sur le développement de projet en Sciences de la Vie. Conférencier invité à l'assemblée générale de l'Institut TransMedTech, Polytechnique, Université de Montréal., Canada
 Main Audience: Knowledge User
 Invited?: No
7. (2022). Cancer cell transcriptomic and epigenomic adaptation to 3D culture. Coriell Institute for Medical Research, Camden, New Jersey, USA., United States of America
 Main Audience: Researcher
 Invited?: Yes
8. Daures M, Poisson M-È, Albert-St-Laurent M, Bianco S, Sgarioto N, Raynal NJ, Gévry N. (2021). Epigenetic screening: Identification of new therapeutic targets in triple-negative breast cancer. Journée Phare 2021, Université de Sherbrooke. Online Congress., Sherbrooke, Canada
 Main Audience: Researcher
 Invited?: Yes

9. (2021). Chromatin status in preclinical cancer models determines therapeutic vulnerability. Conférencier invité aux conférences de l'Axe Maladie Immunitaire et Cancer du CHU Sainte-Justine., Montréal, Canada
Main Audience: Researcher
Invited?: Yes
10. Evelyn Teh, Ken Chisholm, Jeffrey Gallant, Susanne Penny, Noël J-M Raynal, and Nazanin Rohani-Larijani. (2021). Comparative metabolic profiling of cells grown in 2D monolayer vs 3D culture systems. Canadian Cancer Research Conference (CCRC), Online Meeting, Canada
Main Audience: Researcher
Invited?: Yes
11. (2021). Cibler les protéines arginines méthyltransférases dans le cancer du poumon. ACFAS: Organisation des Chromosomes et Stabilité du Génome, Sherbrooke, Canada
Main Audience: Researcher
Invited?: Yes
12. (2020). Using 3D spheroids as a tool to study cancer cell epigenome and perform drug screenings. Conférencier invité à La Série de Séminaires des progrès sur la recherche biomédicales, Faculté de Médecine de l'Université d'Ottawa., Canada
Main Audience: Researcher
Invited?: Yes
13. (2020). Plateforme de criblage moléculaire du CR - CRCHUSJ. Conférencier invité à La Retraite scientifique Département de pharmacologie et physiologie, Université de Montréal., Canada
Main Audience: Researcher
Invited?: Yes
14. (2020). Drug discovery in oncology with 4D spheroids. Conférencier invité chez Admare, TechnoParc, Montréal., Canada
Main Audience: Knowledge User
Invited?: Yes
15. (2020). Découverte de médicaments épigénétiques en oncologie. Conférencier invité aux conférences de l'Axe Maladie Immunitaire et Cancer du CHU Sainte-Justine., Canada
Main Audience: Researcher
Invited?: Yes
16. (2020). 4D spheroid platform as a tool to study cancer cell epigenome and perform drug screenings. Conférencier invité chez Cellesce, UK., United Kingdom
Main Audience: Knowledge User
Invited?: Yes

Publications

Journal Articles

1. Anaïs Darraq, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Alexandra Langford, Oscar Villaneuva, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Serge McGraw, Stéphane Richard, Noël J-M Raynal. (2025). Time-dependent transcriptional and epigenetic changes during 3D non-small cell lung cancer spheroid culture. Submitted. --(--): --.
Last Author
Refereed?: Yes

2. Agata Mostkowska, Guy Rousseau, Noël J-M Raynal. (2024). Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases. *The FASEB Journal*. 38(5): E23536.
 Last Author
 Published
 Refereed?: Yes
 Number of Contributors: 3

3. Marie-Lyn Goyer, Cynthia Deslauniers-Langevin, Anthony Sonn, Georgio Mansour Nehmo, Véronique Lisi, Basma Benabdallah, Noël J-M. Raynal, Christian Beauséjour. (2024). Induced pluripotent stem cell-derived fibroblasts efficiently engage senescence pathways but show increased sensitivity to stress inducers. *Cells*. 13(10): 846.
 Co-Author
 Published
 Refereed?: Yes
 Number of Contributors: 8

4. Elizabeth Elder, Anthony Lemieux, Lisa-Marie Legault, Maxime Caron, Virginie Bertrand-Lehouillier, Noël J-M Raynal, Guillaume Bourque, Daniel Sinnett, Nicolas Gévry, Serge McGraw. (2024). Mouse embryonic stem cells require sustained DNMT1-mediated DNA methylation maintenance for epigenomic, genomic and functional integrity. *Nucleic Acid Research*. --(--): 00.
 Co-Author
 Submitted
 Refereed?: Yes
 Number of Contributors: 10

5. Mia Brunetti, Adrienne L. Jenner, Noël J-M Raynal, Kolja Eppert, Morgan Craig. (2024). Mathematical modelling of acute myeloid leukemia to evaluate clonal reduction therapeutic strategies using drug repurposing. *Leukemia Research*. 140: 107485.
 Co-Author
 Published
 Refereed?: Yes
 Number of Contributors: 5

6. Annie Beaudry, Simon Jacques-Ricard, Anaïs Darracq, Nicolas Sgarioto, Araceli Garcia, Teresita Rode García, William Lemieux, Kathie Béland, Elie Haddad, Paulo Cordeiro, Michel Duval, Serge McGraw, Chantal Richer, Maxime Caron, François Marois, Pascal St-Onge, Daniel Sinnett, Xavier Banquy, and Noël J-M Raynal. (2023). Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and *in vivo* activity with a water/oil emulsion. *Scientific Reports*. 13(1): 16443.
 Last Author
 Published
 Refereed?: Yes
 Number of Contributors: 19

7. Dina Baier, Walter Berger, Theresa Mendrina, Beatrix Schoenhacker-Alte, Christine Pirker, Thomas Mohr, Mate Rusz, Benedikt Regner, Martin Schaier, Nicolas Sgarioto, Noël J-M Raynal, Karin Nowikovsky, Wolfgang Schmidt, Gunda Koellensperger, Samuel Meier-Menches, Petra Heffeter, Bernhard Keppler. (2023). The lipid metabolism as target and modulator of BOLD-100 anticancer activity: crosstalk with histone acetylation. *Advanced Science*. 10(32): 2031939.
 Co-Author
 Published
 Refereed?: Yes
 Number of Contributors: 17

8. Somnath Pandey, Rahinatou Djibo, Anaïs Darracq, Gennaro Calendo, Hanghang Zhang, Ryan A. Henry, Andrew J. Andrews, Steven Baylin, Jozef Madzo, Jaroslav Jelinek, Rafael Najmanovich, Jean-Pierre J. Issa & Noël J.M. Raynal. (2022). Selective CDK9 inhibition by natural compound toyocamycin in cancer cells. *Cancers*. 14: 3340.
Last Author
Published
Refereed?: Yes
Number of Contributors: 13
9. Marielle Huot, Maxime Caron, Chantal Richer, Rahinatou Djibo, Rafael Najmanovich, Pascal St-Onge, Daniel Sinnett & Noël J.M. Raynal. (2021). Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. *Cancer Chemotherapy and Pharmacology*. 88((5)): 845-856.
Last Author
Published
Refereed?: Yes
Number of Contributors: 8
10. Claudia Dominici, Nicolas Sgarioto, Zhenbao Yu, Laura Sesma-Sanz, Jean-Yves Masson, Stéphane Richard and Noël J-M Raynal. (2021). Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. *Clinical Epigenetics*. Mar 10;13((1)): 54-69.
Last Author
Published
Refereed?: Yes
Number of Contributors: 7
11. J. Abusarah, Y. Cui, N. EL-Hachem, AE El-Kadi, I Hammond-Martel, H. Wurtele, A. Beaudry, N J-M Raynal, F. Robert, J. Pelletier, M. Jankovic, F. Mercier, S. Kamyabiazar, B. Annabi, and M. Rafei. (2021). Tacima-218: A Novel Pro-Oxidant Agent Exhibiting Selective Anti-Tumoral Activity. *Molecular Cancer Therapeutics*. Jan;20((1)): 37-49.
Co-Author
Published
Refereed?: Yes
Number of Contributors: 15

Conference Publications

1. Harshini Renganathan, Federico Unger Granados, Anaïs Darracq, Houman Savoji, Noël J-M Raynal. (2025). Impact de la Co-culture 3D sur le Phénotype Cellulaire, les Modifications Transcriptomiques et le Remodelage du Paysage Épigénétique. 39th CHU Sainte-Justine Research Congress.
Poster
Last Author
Published, Invited?: Yes
2. Covida Mootosamy, Noël J-M Raynal, Maja Krajcinovic. (2025). Le traitement personnalisé de la leucémie lymphoblastique aigue chez les enfants ayant une toxicité induite par l'asparaginase. 39th CHU Sainte-Justine Research Congress.
Poster
Co-Author
Published, Invited?: Yes

3. Seyedeh Minoo Alavi, Noël J-M Raynal. (2025). Développement d'un modèle in vitro innovant de co-culture de cellules cancéreuses dans un microenvironnement vascularisé : CUBOID 3D pour la découverte de médicaments. 39th CHU Sainte-Justine Research Congress.
Poster
Last Author
Published, Invited?: Yes
4. Carlos Michel Mourra Diaz, Noël J-M Raynal, Serge McGraw. (2025). Conséquences de la dysrégulation du gène DNMT1 dans le paysage épigénétique : Activation des éléments transposables et formation de transcrits chimeriques dans les cellules souches embryonnaires de souris. 39th CHU Sainte-Justine Research Congress.
Poster
Co-Author
Published, Invited?: Yes
5. Amir Aidun, Houman Savoji, Noël J-M Raynal. (2025). Fabrication et optimisation d'une plateforme de tumeur sur puce pour le cancer du sein et du poumon. 39th CHU Sainte-Justine Research Congress.
Poster
Last Author
Published, Invited?: Yes
6. Elizabeth Elder, Anthony Lemieux, Lisa-Marie Legault, Maxime Caron, Virginie Bertrand-Lehouillier, Thomas Dupas, Noël J-M Raynal, Guillaume Bourque, Daniel Sinnett, Nicolas Gévry, Serge McGraw. (2025). Altérations moléculaires et fonctionnelles dans des cellules souches embryonnaires dépourvues d'une activité soutenue de DNMT1. 39th CHU Sainte-Justine Research Congress.
Poster
Co-Author
Published, Invited?: Yes
7. Federico GRANADOS UNGER, Anaïs Darracq, Noël J-M RAYNAL. (2024). Développement d'un modèle 3D de sphéroïdes de co-culture de cancer du poumon non à petites cellules et de fibroblastes pour la découverte de nouveaux médicaments anticancéreux. 28e édition de la Journée de la recherche Gabriel L. Plaa du Département de pharmacologie et physiologie.
Poster
Last Author
Published, Invited?: Yes
8. Minoo ALAVI, Noël J-M RAYNAL. (2024). Modélisation de la dynamique cellulaire et des changements épigénétiques dans des sphéroïdes 3D avec des hydrogels sur mesure. 28e édition de la Journée de la recherche Gabriel L. Plaa du Département de pharmacologie et physiologie.
Poster
Last Author
Published, Invited?: Yes
9. Anaïs Darracq, Arman Jafari, Minoo Alavi, Noël J-M Raynal, Houman Savoji. (2024). 3D vascularized Tumour Models (CuboidTM) for preclinical validation in oncology. CIHR Institute of Cancer Research Early Career Researcher workshop (Toronto, Canada).
Poster
Co-Author
Published, Invited?: Yes

10. Elizabeth Elder, Anthony Lemieux, Lisa-Marie Legault, Maxime Caron, Virginie Bertrand-Lehouillier, Noël Raynal, Guillaume Bourque, Daniel Sinnett, Nicolas Gévry, Serge McGraw. (2024). Mouse Embryonic Stem Cells Require Sustained Dnmt1-Mediated DnaMethylation Maintenance For Epigenomic, Genomic And Functional Integrity.17th Symposium of Réseau Québécois en reproduction.
Poster
Last Author
Published, Invited?: Yes
11. Federico Granados Unger, Anaïs Darracq, Noël J-M Raynal. (2024). Impact de la co-culture 3D sur le transcriptome et le phénotype cellulaire.38e Congrès de la recherche du CHU Sainte-Justine (Montréal, Février 01-02, 2024)
Poster
Last Author
Published, Invited?: Yes
12. Elizabeth Elder, Anthony Lemieux, Lisa-Marie Legault, Maxime Caron, Virginie Bertrand-Lehouillier, Noël J-M Raynal, Guillaume Bourque, Daniel Sinnett, Nicolas Gévry, Serge McGraw. (2024). Mouse embryonic stem cells require sustained dnmt1-mediated dnamethylation maintenance for epigenomic, genomic and functional integrity.2024 RQR Symposium.
Poster
Co-Author
Published, Invited?: Yes
13. Anthony Sonn, Georgio Mansour Nehmo, Noël J-M Raynal, Christian Beauséjour. (2024). Pharmacologie ciblée : Augmenter la sensibilité des cellules sénescences à la cytotoxicité des Natural Killer.39th CHU Sainte-Justine Research Congress.
Poster
Co-Author
Published, Invited?: Yes
14. Anaïs Darracq, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Mariya Kryvoshey, Nazanin Rohani Larijani, Anne E.G. Lenferink, Alexandra Langford, Oscar Villaneuva, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Stéphane Richard, Serge McGraw & Noël J-M Raynal. (2024). Time-dependent chromatin maturation 3D spheroids improves preclinical modeling of non-small cell lung cancer.CEEHRC 10th Annual Canadian Conference on Epigenetics, Blue Mountains, Ontario from October 1 to 4, 2024.
Poster
Last Author
Published, Invited?: Yes
15. Anaïs DARRACQ, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Mariya Kryvoshey, Nazanin Rohani Larijani, Anne E.G. Lenferink, Alexandra Langford, Oscar Villaneuva, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Stéphane Richard, Serge McGraw & Noël J-M Raynal. (2024). La culture 3d de sphéroïdes impose une adaptation de la chromatine tempsdépendante qui permet de mimer le transcriptome tumoral du cancer du poumon non à petites cellules.28e édition de la Journée de la recherche Gabriel L. Plaa du Département de pharmacologie et physiologie.
Poster
Last Author
Published, Invited?: Yes

16. Anaïs Darracq, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Mariya Kryvoshey, Nazanin Rohani Larijani, Anne E.G. Lenferink, Alexandra Langford, Oscar Villaneuva, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Stéphane Richard, Serge McGraw & Noël J-M Raynal. (2024). Time-dependent chromatin maturation 3D spheroids improves preclinical modeling of non-small cell lung cancer. 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, Barcelone, Espagne (ENA24-0402).
Poster
Last Author
Published, Invited?: Yes
17. Anaïs Darracq, Noël J-M Raynal. (2024). Type I PRMT and KDM4 therapeutic vulnerability in non-small cell lung cancer spheroids. 38e Congrès de la recherche du CHU Sainte-Justine (Montréal, Février 01-02, 2024).
Poster
Last Author
Published, Invited?: Yes
18. Anaïs Darracq, Nicolas Sgarioto, Marielle Huot, Gabrielle McInnes, Elisa Clement, Antoine Meant, Mariya Kryvoshey, Nazanin Rohani Larijani, Anne E.G. Lenferink, Alexandra Langford, Oscar Villaneuva, François Marois, Maxime Caron, Pascal Saint-Onge, Severine Leclerc, Gaël Cagnone, Gregor Andelfinger, Daniel Sinnett, Stéphane Richard, Serge McGraw & Noël J-M Raynal. (2023). Time-dependent maturation of transcriptomic and epigenomic profiles in 3D cancer spheroids to improve preclinical models and drug screenings. Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Last Author
Published, Invited?: Yes
19. Federico Granados Unger, Anaïs Darracq, Noël Raynal. (2023). Impact de la co-culture 3d sur le transcriptome et le phénotype cellulaire. Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Last Author
Published, Invited?: Yes
20. Evelyn M. Teh, Susanne Penny, Séverine Landais, Marielle Huot, Claire Moore, Andrew Leslie, Zhaolin Xu, Anne Lenferink, Noël J-M Raynal, and Nazanin Rohani Larijani. (2023). Mimicking tumour acidosis and hypoxic microenvironment in vitro; towards generation of a more predictive drug screening platform for solid tumours. The Canadian Cancer Research Conference (November 12-14, 2023, Halifax)
Poster
Co-Author
Published, Invited?: Yes
21. Rahinatou Djibo, Noël J-M Raynal, Rafael Najmanovich. (2023). IDENTIFICATION DESCIBLES MOLECULAIRES ALTERNATIVES DE LA PROSCILLARIDIN A DANS LES CANCERS MYC-DÉPENDANTS. Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Co-Author
Published, Invited?: Yes
22. Nazanin Rohani, Noël Raynal, Anne Lenferink. (2023). Modeling tumour microenvironment acidosis and hypoxia using 3D spheroids of non-small cell lung cancer and their impact on anticancer drug effects. Symposium annuel du CHU Sainte-Justine et du Conseil national de recherches du Canada.
Poster
Co-Author
In Press, Invited?: Yes

23. Mia Brunetti, Adrienne Jenner, Noël J-M Raynal, Kolja Eppert, Morgan Craig. (2022). Mathematical modelling of hematopoiesis during AML to evaluate clonal reduction therapeutic strategies using drug repurposing.Till & McCulloch Meetings from the Stem Cell network.
Poster
Co-Author
Published, Invited?: Yes
24. Noël J-M Raynal. (2022). Type I and KDM4 therapeutic vulnerability in non-small cell lung cancer spheroids.Canadian Conference on Epigenetics (Estérel, Québec) for the Canadian Epigenetics, Environment and Health Research Consortium Network.
Poster
First Listed Author
Published, Invited?: Yes
25. Anaïs Darracq et Noël J-M Raynal. (2022). Développement de médicaments ciblant un nouveau modèle de sphéroïdes de cancer du sein triple-négatif.Canadian Conference on Epigenetics (Estérel, Québec) for the Canadian Epigenetics, Environment and Health Research Consortium Network
Poster
Last Author
Published, Invited?: Yes
26. Anaïs Darracq et Noël J-M Raynal. (2022). Développement de médicaments ciblant un nouveau modèle de sphéroïdes de cancer du sein triple négatif.Canadian Pharmacology Annual Meeting (Montréal Qc).
Poster
First Listed Author
Published, Invited?: Yes
27. Noël J-M Raynal. (2022). Type I and KDM4 therapeutic vulnerability in non-small cell lung cancer spheroids.Canadian Pharmacology Annual Meeting (Montréal Qc).
Poster
First Listed Author
Published, Invited?: Yes
28. Emmanuel Sy et Noël J-M Raynal. (2022). Étude de l'impact de la co-culture en 3D de fibroblastes sur le comportement des cellules du cancer du poumon.Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Last Author
Accepted, Invited?: Yes
29. Anaïs Darracq et Noël J-M Raynal. (2022). Développement de médicaments ciblant un nouveau modèle de sphéroïdes de cancer du sein triple négatif.Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Last Author
Accepted, Invited?: Yes
30. Mardhy Walid, Mariya Kryvoshey, Noël J-M Raynal. (2022). Développement de modèles précliniques de sphéroïdes de neuroblastomes en co-culture avec des cellules NK.Journée Gabriel L. Plaa du département de pharmacologie et physiologie, Udm.
Poster
Last Author
Accepted, Invited?: Yes

31. Rohani Larijani, Marielle Huot, Anne Lenferink, and Noël J-M Raynal. (2022). Mimicking tumoracidic and hypoxic microenvironment in vitro towards generation of morepredictive screening platform for solid tumors.AACR Special Conference Evolutionary Dynamics in Carcinogenesis and Response to Therapy. Poster
Last Author
Accepted, Invited?: Yes

Intellectual Property

Patents

1. PCT patent application: DEVICE FOR THE PREPARATION OF VASCULARIZED 3D CELL CULTURE SYSTEMS AND USES THEREOF. United States of America. 63/495,574. 2024/04/12.
Patent Status: Pending
Year Issued: 2024
2. Alveo Cell : Arman Jafari, Houman Savoji, Noël J.-M. Raynal.United States of America. 63/495,574. 2023/04/12.
Patent Status: Pending
Year Issued: 2023
3. Cytosine nucleoside analogs and isoflavones and uses thereof. Canada. Canadian Intellectual Property Office CA 2590048. 2007/05/23.
Patent Status: Granted/Issued
Year Issued: 2013
4. Cytosine nucleoside analogs and isoflavones and uses thereof. United States of America. USPTO No: 12/126,493. 2008/05/23.
Patent Status: Granted/Issued
Year Issued: 2011

Date Submitted: 2025-01-20 11:50:04

Confirmation Number: 1897075

Template: CIHR Biosketch

Mr. Thomas Gervais

Correspondence language: French

Sex: Male

Date of Birth: 12/06

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

École Polytechnique de Montréal
Department of Engineering Physics
Room B582.2
C.P. 6079, succ. Centre-Ville
Montréal Quebec H2G 2R9
Canada

Telephone

Work (*) +1-514-340-4711 extension: 3752

Email

Work (*) thomas.gervais@polymtl.ca

Website

Corporate <http://www.polymtl.ca/recherche/rc/en/professeurs/details.php?NoProf=428>



Protected when completed

Mr. Thomas Gervais

Degrees

2000/9 - 2006/2	Doctorate, Philosophiae Doctor, Massachusetts Institute of Technology Degree Status: Completed
1995/9 - 2000/5	Bachelor's, Bachelor of engineering, École Polytechnique de Montréal Degree Status: Completed

Credentials

2014/3	ing. (P. Eng.), Ordre des ingénieurs du Québec (OIQ)
--------	--

Recognitions

2021/4	Meritas - Best graduate lecturer in biomedical engineering École Polytechnique de Montréal
2017/4 - 2017/4	Meritas/Teaching Award - Best graduate lecturer in biomedical engineering École Polytechnique de Montréal
2016/3	Méritas d'enseignement / Teaching Award École Polytechnique de Montréal
2012/6 - 2012/6	AJIQ - Grand prix du journalisme indépendant Association des journalistes indépendants du Québec (AJIQ)
2011/6 - 2011/6	Grand prix du journalisme indépendant du Québec Association des journalistes indépendants du Québec (AJIQ)

Employment

2019/6	Professor of engineering physics and biomedical engineering Engineering Physics, Polytechnique Montreal, École Polytechnique de Montréal
2019/8 - 2020/7	Research Scientist IBM Research - Zurich
2016/6 - 2019/5	Associate professor of engineering physics and biomedical engineering Engineering physics, École Polytechnique de Montréal, École Polytechnique de Montréal
2013/1 - 2016/6	Assistant professor Engineering Physics, Polytechnique Montréal, École Polytechnique de Montréal
2009/7 - 2012/12	Senior Lecturer (Chargé d'enseignement) Génie physique, Polytechnique Montréal, École Polytechnique de Montréal

2006/3 - 2012/12 Science communicator
Communications Scientifiques Thomas Gervais

Affiliations

The primary affiliation is denoted by (*)

(*) 2013/1 Associate Professor of Engineering Physics, Engineering Physics, École Polytechnique de Montréal

Research Funding History

Awarded [n=10]

2023/5 - 2026/4 Co-applicant	Unveiling metabolic cooperation between glycerol and lactate as the driver of Funding Sources: Natural Sciences and Engineering Research Council of Canada (NSERC) New Frontiers of Research Funds - Exploration Total Funding - 200,000 Funding Competitive?: Yes Co-applicant : Fred Saad; Gerardo Ferbeyre; Marc Prentki; Pierre Chaurand
2022/9 - 2025/8 Principal Investigator	Mass manufacturable perfusion-free microfluidics systems for 3D oncology Funding Sources: TransMedTech Institute TransMedTech INstitute grant Total Funding - 177,000 Funding Competitive?: Yes
2020/4 - 2025/4 Principal Applicant	Advanced reagent delivery systems for microfluidics Funding Sources: Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant Total Funding - 195,000 Funding Competitive?: Yes
2020/4 - 2025/4 Co-applicant	Exploring epithelial ovarian cancer cell senescence as a clinical biomarker and drug target Funding Sources: Canadian Institutes of Health Research (CIHR) Project grant Total Funding - 1,330,000 Funding Competitive?: Yes Co-applicant : Diane Provencher; Collaborator : Anne-Marie Mes-Masson; David Huntsman; François-Michel Boisvert; Rejean Lapointe; Principal Applicant : Francis Rodier
2019/9 - 2024/5 Collaborator	Dosimetric and radiobiologic characterization and development of a novel technology for intratumoral radiotherapy with alpha particles (DaRT) using microfluidic Lab-on-a- chip technology (LOC) Funding Sources: Canada First/Apogee Initiative TransMedTech institute

	Total Funding - 700,000 Funding Competitive?: Yes Co-applicant : François Deblois; Philip Wong; Principal Applicant : Yuji Kamio
2021/1 - 2024/1 Co-investigator	Développement et caractérisation dosimétrique et biologique d'une nouvelle technologie de radiothérapie intra-tumorale par particules alpha (DaRT) à l'aide de microdispositifs microfluidiques. Funding Sources: Canada First/Apogee Transmedtech Institute Total Funding - 300,000 Funding Competitive?: Yes Co-investigator : Yuji Kamio
2021/10 - 2023/8 Principal Investigator	Maturation d'un système de culture de tumeurs microdisséquées sur puces Funding Sources: Ministère de l'économie et de l'innovation du Québec Programme de soutien aux organisations (PSO) Total Funding - 187,500 Funding Competitive?: Yes
2020/6 - 2023/6 Principal Applicant	Mycotoxines sur puces: analyse de la réponse inflammatoire de pathogènes nouvellement présents dans l'alimentation Funding Sources: Fonds de recherche du Québec - Nature et technologies (FRQNT) Samuel de Champlain Total Funding - 26,000 Funding Competitive?: Yes
2020/5 - 2023/5 Principal Applicant	Afficheurs microfluidiques reconfigurables pour la stimulation dynamique de voies de signalisations cellulaires. Funding Sources: Fonds de recherche du Québec - Nature et technologies (FRQNT) Équipe Total Funding - 150,000 Funding Competitive?: Yes Co-applicant : Laurent Potvin-Trottier
2022/10 - 2023/4 Principal Applicant	Système de culture de tumeurs microdisséquées sur puces Funding Sources: Ministère du développement économique, de l'innovation et de l'exportation (MDEIE) PSO Total Funding - 187,500 Funding Competitive?: Yes
Completed [n=7]	
2018/4 - 2022/10 Principal Applicant	muFO 1. From experimental platform to clinical innovation: empirical drug sensitivity testing for personalized medicine in oncology. Funding Sources: TransMedTech Institute Operating grant

2018/4 - 2022/10 Principal Applicant	Total Funding - 175,000 Funding Competitive?: Yes muFO 2: SPHERAD: Spheroid phenotyping under radiation- chip- based treatment response assays for anti-cancer drug discovery and repurposing Funding Sources: TransMedTech Institute Operating grant Total Funding - 175,000 Funding Competitive?: Yes
2017/5 - 2022/4 Principal Applicant	Transformation microfluidics: Theory and applications of energy and mass cloaking in fluids Funding Sources: Fonds de recherche du Québec - Nature et technologies (FRQNT) Équipe Total Funding - 229,198 Funding Competitive?: Yes Co-applicant : David Juncker
2021/1 - 2022/1 Principal Applicant	Sciences & médias : l'essentiel pour des communications réussies Funding Sources: Natural Sciences and Engineering Research Council of Canada (NSERC) Z-Promoscience Total Funding - 30,000 Funding Competitive?: Yes
2014/7 - 2020/7 Principal Applicant	Open microfluidics platforms for the in vitro assessment of drug transport in microtumour samples Funding Sources: Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant Total Funding - 180,000 Funding Competitive?: Yes
2015/6 - 2020/6 Co-investigator	Infrastructure for Micro-Imaging and Optical Glass Processing (# 33372) Funding Sources: Canada Foundation for Innovation (CFI) Innovation Fund (project # 33372) Total Funding - 2,331,377 Funding Competitive?: Yes Co-investigator : Caroline Boudoux; Denis Lafrance; Frédéric Leblond; Julien Cohen-Adad; Michael D. Buschmann; Michel Meunier; Mohamad Sawan; Yves-Alain Peter; Principal Investigator : Frédéric Lesage
2018/5 - 2020/5 Principal Applicant	Laboratoires-sur-puce pour l'identification systématique de synergies thérapeutiques entre radiothérapie et chimiothérapie Funding Sources: Fonds de recherche du Québec - Société et culture (FRQSC) AUDACE Total Funding - 100,000 Funding Competitive?: Yes Co-applicant : Philip Wong

Under Review [n=1]

2023/8 - 2025/7 Imaging drug distribution and response in tumors using microfluidics and imaging mass spectrometry
Principal Applicant

Funding Sources:

Cancer Research Society (The)

Operating grant

Total Funding - 125,000

Funding Competitive?: Yes

Publications**Journal Articles**

1. Rodin Chermat Elena Refet-Mollof Yuji Kamio Jean-François Carrier Philip Wong Thomas Gervais. (2024). Brachytherapy on-a-chip: a clinically-relevant approach for radiotherapy testing in 3D biology. Lab Chip. 1(1): 1-12.
Accepted
Refereed?: Yes, Open Access?: No
2. Julien Bissonnette-Dulude, Pepijn Heirman, Sylvain Coulombe, Annemie Bogaerts, Thomas Gervais, Stephan Reuter. (2024). Coupling the COST reference plasma jet to a microfluidic device: a computational study. Plasma sources science and technology. 33(1): 1-12.
Published
Refereed?: Yes, Open Access?: No
3. Dorrigiv D. Goyette P.A. St-Georges-Robillard A. Mes-Masson A.M. Gervais T. (2023). Pixelated microfluidics for drug screening on tumour spheroids and ex vivo microdissected tumor explants. Cancers. 157(4): 1060.
Published
Refereed?: Yes, Open Access?: Yes
4. Samuel Castonguay, Yuksel Temiz, Emmanuel Delamarche, Thomas Gervais. (2023). Reverse Washburn dynamics induces flow acceleration during capillary filling. Physics of fluids. 35(112107): 1-7.
Published
Refereed?: Yes, Open Access?: No
5. Boulais E, Gervais T. (2023). The 2D microfluidic cookbook - Modeling convection and diffusion in plane flow devices. Lab Chip. 1: 1-14.
Accepted
Refereed?: Yes, Open Access?: No
6. Bissonnette-Dulude J. Coulombe S. Gervais T. Reuter S. (2023). Coupling the COST reference plasma jet to a microfluidic device: a new diagnostic tool for plasma-liquid interactions. Plasma Sources Science and Technology. 1: 1-10.
Accepted
Refereed?: Yes, Open Access?: No
7. Gervais T., Temiz Y., Aubé L.*, Delamarche E. (2022). Large-scale dried reagent reconstitution and diffusion control using microfluidic self-coalescence module s. Small. 1(2105939): 1-10.
Published
Refereed?: Yes
8. Boyadjian O.*, Boulais E.*, Gervais T. (2022). Microfluidic surface shields: Control of flow and diffusion over sensitive surfaces". Physical Review Applied. 014012: 1-10.
Published
Refereed?: Yes

9. Chermat R.*, Ziaee M.*, Mak D., Refet-Mollof E.*, Rodier F., Carrier J.-F., Wong P., Kamio Y., Gervais T., (2022). Radiotherapy on-chip: microfluidics for translational radiation oncology. *Lab Chip*. 22: 2065-2079.
Published
Refereed?: Yes
10. Rocca M., Temiz Y., Salva M., Castonguay S.*, Gervais T., Niemeyer C., Delamarche E. (2021). Rapid quantitative assays for glucose-6-phosphate dehydrogenase (G6PD) and hemoglobin combined on a capillary-driven microfluidic chip. *Lab Chip*. 21(18): 3573-3582.
Published
Refereed?: Yes, Open Access?: No
11. Castonguay S.*, Gervais T. (2021). A simple static contact angle-based mesh-dependency correction for 3D capillary flow simulations. *Computers & Fluids*. 228(Computers): 1-8.
Published
Refereed?: Yes
12. Dorrigiv D.*, Simeone K., Communal L., Kendall-Dupont J., St-Georges-Robillard A.*, Péant B., Carmona E., Mes-Masson A.-M., Gervais T. (2021). Microdissected Tissue vs Tissue Slices—A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. *Cancers*. 13(16): 4208.
Published
Refereed?: Yes, Open Access?: Yes
13. Goyette, Pierre-Alexandre* Boulais, Étienne* Tremblay, Maude* Gervais, Thomas. (2021). Pixel-based open-space microfluidics for versatile surface processing. *Proceedings of the National Academy of Sciences of the United States of America (PNAS)*. 118(2): 1-7.
Published
Refereed?: Yes, Open Access?: No
14. Refet-Mollof E.*, Najyb O.*, Chermat R.*, Glory A., Lafontaine J., Wong P., Gervais T. (2021). Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy. *Cancers*. 13(16): 4046.
Published
Refereed?: Yes, Open Access?: Yes
15. Bavoux, Maeva* Kamio, Yuji Vigneux-Foley, Emmanuelle* Lafontaine, Julie Najyb, Ouafa* Refet-Mollof, Elena* Carrier, Jean-François Gervais, Thomas Wong, Philip. (2021). *X-Ray on chip: quantifying therapeutic synergies between radiotherapy and anticancer drugs using soft tissue sarcoma tumor spheroids*. *Radiotherapy and Oncology*. 157(April 2021): 175-181.
Published
Refereed?: Yes, Open Access?: No
16. Patra, Bishnubrata* Lateef, Muhammad Abdul Nourmoussavi-Brodeur, Mélica Fleury, Hubert Carmona, Euridice Péant, Benjamin Provencher, Diane Mes-Masson, Anne-Marie Gervais, Thomas. (2020). Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. *PlosOne*. 1: 1-17.
Published
Refereed?: Yes, Open Access?: Yes
17. Boulais, Étienne* Gervais, Thomas. (2020). 2-Dimensional Convection-Diffusion in Multipolar Flows with Applications in Microfluidics and Groundwater Flow. *Physics of Fluids*. 32(122001): 1-12.
Published
Refereed?: Yes, Open Access?: No
- [18.](#) St-Georges-Robillard A.*, Cahuzac M., Péant B., Fleury H., Lateef MA., Ricard A., Sauriol A., Leblond F., Mes-Masson A.-M., Gervais T. (2019). Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution. *Integrative Biology*. 11(4): 130-141.
Published
Refereed?: Yes, Open Access?: No

19. Cao Y, Nallappan K, Guerboukha H, Gervais T, Skorobogatiy M. (2019). Additive manufacturing of resonant fluidic sensors based on photonic bandgap waveguides for terahertz applications. *Optics Express*. 27(20): 1-16.
Published
Refereed?: Yes, Open Access?: Yes
- [20.](#) Gökçe O., Castonguay S., Temiz Y., Delamarche E., Gervais T. (2019). Self-coalescing flows in microfluidics for pulse-shaped delivery of reagents. *Nature*. 574: 228-235.
Published
Refereed?: Yes, Open Access?: No
21. Simeone, Kayla Guay-Lord, Robin* (co-first author), Lateef MA, Péant B, Kendall-Dupont J, Orimoto AM, Carmona E, Provencher D, Saad F, Gervais T (co-corresponding author), Mes-Masson AM. (2019). **Paraffin-embedding lithography and Micro-dissected tissue microarrays : tools for biological and pharmacological analysis of ex vivo solid tumors**. *Lab Chip*. -: -.
Published
Refereed?: Yes
- [22.](#) Patra B.*, Lafontaine J, Bavoux, M.* Zerouali, K Glory A, Ahanj M, Carrier JF, Gervais T, Wong P. (2019). On-Chip combined radiotherapy and chemotherapy on soft tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assays. *Scientific Reports*. 9: 2214.
Published
Refereed?: Yes, Open Access?: Yes
23. Goyette P.-A.*, Boulais E.*, Laberge G.*, Normandeau F., Juncker D., Gervais T. (2019). Microfluidic multipoles theory and applications. *Nature Communications*. 10: 1-10.
Published
Refereed?: Yes, Open Access?: Yes
24. Marimuthu M.*, Rousset N.*, St-Georges-Robillard A.*, Lateef MA, Ferland M.*, Mes-Masson AM, Gervais T. (2018). Multi-Size spheroid formation using microfluidic funnels. *Lab Chip*. 18: 304-314.
Published
Refereed?: Yes, Open Access?: No
25. St-Georges-Robillard A.*, Masse M.*, Strupler M., Patra B.*, Orimoto A.M., Kendall-Dupont J., Péant B., Mes-Masson A.-M., Leblond F., Gervais T. (2018). Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips. *Analyst*. 143(16): 3829-3840.
Published
Refereed?: Yes, Open Access?: No
26. Brimmo AT, Goyette P.-A.* (co-first author), Alnemari R., Gervais T. (co-corresponding author), Qasaimeh M.A. (2018). 3D-printed microfluidic probes. *Scientific Reports*. 8(1): 10995.
Published
Refereed?: Yes

Book Chapters

- [1.](#) Lafontaine J. Refet-Mollof E. Najyb O. Gervais T. Wong P. (2023). Cell death analysis in cancer spheroids from a microfluidic device. Bercenilla H. Diaz D. *Apoptosis and Cancer: Methods and Protocols*. Springer Protocols: 13-25.
Published, Humana New York, United States of America
2. Étienne Boulais, Thomas Gervais. (2018). Hele shaw flow theory in the context of open microfluidics : from dipoles to quadrupoles. Emmanuel Delamarche, Govind Kaigala. *Open Space Microfluidics. Concepts, Implementations, Applications.*: 63-82.
Published, Wiley-VCH Verlag GmbH & Co, Germany

3. Robin Guay-Lord, Muhammed Abdul Lateef, Kayla Simeone, Benjamin Péant, Jennifer Kendall-Dupont, Anne-Marie Mes-Masson, Thomas Gervais, Fred Saad,. (2018). Microfluidic Devices and Micro-Dissected Tissue to Predict Therapeutic Response in Patients with Prostate Cancer. Huifang Chen Paulo N Martins. *Advances in Experimental Surgery*. Volume 2. : 183-210.
Published, Nova Science, United States of America

Conference Publications

1. Dorrigiv, Dina Simeone, Kayla Péant, Benjamin Carmona, Euridice Kendall-Dupont, Jennifer Mes-Masson, Anne-Marie Gervais, Thomas. Microdissected tumors have lower hypoxia, apoptosis, and necrosis and higher proliferation than tumor slices cultured in similar conditions. The 24th international conference on miniaturization in chemistry and the life sciences (microTAS),
Paper
Refereed?: Yes, Invited?: No
2. Boulais E, Boyadjian-Braize O, Gervais T,. The O-filter: a surface invisibility cloak for selective surface chemistry. The 25th international conference on miniaturization in chemistry and the life sciences (microTAS), Palm Springs, United States of America
Conference Date: 2021/10
Paper
Refereed?: Yes, Invited?: No
3. Gervais T, Temiz Y, Aubé L, Delamarche E,. Self-coalescence module arrays for large scale reagent reconstitution and diffusion-controlled experiment. The 25th international conference on miniaturization in chemistry and the life sciences (microTAS), Palm Springs, United States of America
Conference Date: 2021/10
Paper
Refereed?: Yes, Invited?: No
4. Dorrigiv D, Simeone K, Péant B, Carmona E, Kendall-Dupont J, Mes-Masson AM, Gervais T. Ex vivo tumors on chip- a comparative study of microdissected tissue and tissue slices. The 25th international conference on miniaturization in chemistry and the life sciences (microTAS), Palm Springs, United States of America
Conference Date: 2021/10
Poster
Refereed?: Yes, Invited?: No
5. Refet-Mollof E, Najyb O, Chermat R, Glory A, Lafontaine J, Wong P, Gervais T. HONACHIP (hypoxia on a chip) : insights into treatment efficacy. The 25th international conference on miniaturization in chemistry and the life sciences (microTAS), Palm Springs, United States of America
Conference Date: 2021/10
Poster
Refereed?: Yes, Invited?: No
6. Goyette, Pierre-Alexandre Gervais, Thomas. **Pixelated chemical displays for dry surface patterning in industrial roll-to-roll processes**. The 24th international conference on miniaturization in chemistry and the life sciences (microTAS),
Conference Date: 2020/10
Paper
Refereed?: Yes, Invited?: No
7. Refet-Mollof, Elena Najyb, Ouafa Chermat, Rodin Lafontaine, Julie Wong, Philip Gervais, Thomas. **A simple method to analyze natural hypoxia expression in jumbo spheroids on-chip** . the 24th international conference on miniaturization in chemistry and the life sciences (microTAS),
Conference Date: 2020/10
Paper
Refereed?: Yes, Invited?: No

8. Refet-Mollof* E, Najyb* O, Bavoux* M, Lafontaine J, Wong P, Gervais T. Conception of a microfluidic chip for pre-clinical evaluation of radiation and drug sensitivity : The role of hypoxia. CRUK-AACR Joint Conference on Engineering and Physical Sciences in Oncology, London, United Kingdom
Conference Date: 2019/10
Poster
Refereed?: Yes, Invited?: No
9. Goyette* PA, Dorrigiv* D, Tremblay* M, Simeone K, Gervais T. Pixelated chemical displays: towards massively parallel dynamic surface processing. 23rd international conference on miniaturization in Chemistry and the life sciences (microTAS), Basel, Switzerland
Conference Date: 2019/10
Paper
Refereed?: Yes, Invited?: No
10. Bavoux* M, Kamio Y, Lafontaine J, Gervais T, Wong P. Optimization of a microfluidic system for high-throughput screening of combinations of drugs with radiotherapy on spheroids (Best poster prize). World Pharma Week, Boston, United States of America
Conference Date: 2019/6
Poster
Refereed?: Yes, Invited?: No
11. Goyette* PA, Boulais* E, Laberge* G, Normandeau F, Juncker D, Gervais T. Reconfigurable multipolar open-space microfluidics. 22nd International conference on miniaturization in chemistry and the life sciences (microTAS), Kaohsiung, Taiwan
Conference Date: 2018/11
Paper
Refereed?: Yes, Invited?: No
12. Goyette* PA, Gervais T. 3D-printed microfluidic probes and reagent displays. 22nd International conference on miniaturization in chemistry and the life sciences (microTAS), Kaohsiung, Taiwan
Conference Date: 2018/11
Poster
Refereed?: Yes, Invited?: No
13. Boulais* E, Goyette* PA, Gervais T. Understanding convection-diffusion in open-space microfluidics via conformal mapping. 22nd International conference on miniaturization in chemistry and the life sciences (microTAS), Kaohsiung, Taiwan
Conference Date: 2018/11
Poster
Refereed?: Yes, Invited?: No
14. Simeone* K, Guay-Lord* R (co-first author), Lateef MA, Péant B, Carmona E, Kendall-Dupont J, Orimoto AM, Provencher D, Saad F, Mes-Masson AM, Gervais T. Micro-dissected tissue microarrays for drug discovery and therapeutic response assays on ex vivo tumor samples. 22nd International conference on miniaturization in chemistry and the life sciences (microTAS), Kaohsiung, Taiwan
Conference Date: 2018/11
Poster
Refereed?: Yes, Invited?: No
15. St-Georges-Robillard* A, Cahuzac M, Sauriol A, Péant B, Mes-Masson AM, Leblond F, Gervais T. Quantifying Parpi-resistant subpopulations after treatment in co-culture spheroids using hyperspectral imaging. 22nd International Conference on miniaturization in chemistry and the life sciences (microTAS), Kaohsiung, Taiwan
Conference Date: 2018/11
Poster
Refereed?: Yes, Invited?: No

Intellectual Property

Patents

1. Cell culture devices. United States of America. 63/420,834. 2022/10/31.
Patent Status: Pending
2. System and method of fluid delivery. United States of America. 101860-004. 2018/10/01.
Patent Status: Granted/Issued
Year Issued: 2023
3. Medium-embedded samples. United States of America. 11,513,041. 2018/10/19.
Patent Status: Granted/Issued
Year Issued: 2022
4. Method and system of magnetic separation of rare earths. United States of America. US13/822,363.
2012/08/15.
Patent Status: Withdrawn
Year Issued: 2013

Presentations

1. (2023). Theory-guided innovation in microfluidics for point-of-care diagnostics and oncology. Seminar, Department of Materials, Invited by Prof. Molly M. Stevens, Imperial College London, United Kingdom
Main Audience: Researcher
Invited?: Yes, Keynote?: No
2. (2020). 3D culture, reagent delivery, and bioassay development using microfluidics – From theory-guided design to practical implementation. Seminar in microsystems engineering, Netherlands
Main Audience: Researcher
Invited?: Yes, Keynote?: No
3. (2020). 3D culture, reagent delivery, and bioassay development using closed- and open-space microfluidics. Applied Biosciences Seminar, Switzerland
Main Audience: Researcher
Invited?: Yes, Keynote?: No
4. (2020). 3D culture, reagent delivery, and bioassay development using closed- and open-space microfluidics. ARTORG seminar - Bern University, Switzerland
Main Audience: Researcher
Invited?: Yes, Keynote?: No
5. (2019). 3D culture, reagent delivery, and bioassay development in closed- and open-space microfluidics – From theory-guided design to practical implementation. Seminar series in Physics - École Polytechnique Fédérale de Lausanne, Switzerland
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Student/Postdoctoral Supervision

Bachelor's [n=1]

2022/5 - 2022/8 Tommy Brasseur, Polytechnique Montréal
Principal Supervisor Thesis/Project Title: Summer internship in Biomedical Engineering
Present Position: Undergraduate student in Engineering Physics

Master's Equivalent [n=1]

2018/9 - 2020/8 Elena Refet-Mollof, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Jumbo spheroid synthesis and applications in radiobiology.
 Present Position: PhD Student

Master's Thesis [n=2]

2023/8 - 2024/8 Raphaël Fillion, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Development of Microfluidics culture vessels for 3D biology
 Present Position: M.Sc. Candidate in biomedical engineering

2022/8 - 2024/8 Maude Proulx, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Dynamic stimulation of the Notch pathway using open-space microfluidics
 Present Position: M.Sc. Candidate in Biomedical Engineering

Doctorate [n=6]

2024/1 Sara Ghasemi, Polytechnique Montréal
 Academic Advisor Thesis/Project Title: Glycerol metabolism in prostate cancer explants
 Present Position: Ph.D. Candidate

2021/8 - 2025/8 Marie Amate, Polytechnique Montreal
 Co-Supervisor Thesis/Project Title: Microbubble delivery to organs-on-chip
 Present Position: Ph.D. Candidate

2021/1 - 2025/12 Maryam Ziaee, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Effects of non-thermal plasma and radiotherapy on tissue explants cultured on-chip
 Present Position: Ph.D. Student

2021/1 - 2025/1 Rodin Chermat, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Brachytherapy on-chip - principles, designs and applications to soft tissue sarcoma treatments
 Present Position: PhD Student

2020/9 - 2024/5 Elena Refet-Mollof, Polytechnique Montréal
 Principal Supervisor Thesis/Project Title: Studies of hypoxia effect on drug and radiotherapy treatment in naturally hypoxic spheroids
 Present Position: PhD Student

2016/1 - 2023/12 Étienne Boulais, École Polytechnique de Montréal
 Principal Supervisor Thesis/Project Title: Understanding 2D transport in microfluidics
 Present Position: Ph.D. Student